{3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-2-oxo-1,3-dihydro-1.3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine derivatives and similar compounds as PARG inhibitors for the treatment of cancer

Abstract

The present invention relates to compounds of Formula (I) wherein Q is NH or CH2; and wherein B is one of formula (a) to (k) which are inhibitors of PARG and are useful in the treatment of cancer.

Description

[0001] Attorney Docket No.: 53238-0005WO1 INHIBITORS OF PARG CROSS-REFERENCE TO RELATED APPLICATION This application claims the benefit of U.S. Provisional Application Nos.63 / 518,738, filed August 10, 2023, and 63 / 658,747, filed June 11, 2024, the disclosures of which are incorporated herein by reference in their entirety. FIELD OF THE INVENTION The present invention relates to sulfonamides and related compounds which are inhibitors of PARG and are useful in the treatment of cancer. BACKGROUND OF THE INVENTION Cancer is a disease caused by abnormal and unregulated cell division. One of the hallmarks of cancer is the up or downregulation of cellular stress pathways which the cancer cells or tumor use for a proliferative advantage. These cellular stress pathways often include, but are not limited to, oxidative stress, DNA damage stress, DNA replicative stress, transcriptional stress, hypoxia, and others. ADP-ribose, as well as the enzymes that generate ADP-ribose (Poly(ADP-ribose) polymerases or PARPs) and hydrolyze ADP-ribose (Poly(ADP-ribose) glycohydrolases or PARGs), play critical roles in regulating cellular stress responses. There are two forms of ADP-ribose in the cell, mono(ADP-ribose) (MAR) and Poly(ADP-ribose) (PAR). Both forms of ADP-ribose are generated by a family of 17 PARP proteins, whose key roles in the cell are to regulate cellular stress responses (Cohen MS, Chang P. Nat Chem Biol.2018). In humans, PARG exists as a single gene with 3 splicing isoforms. These isoforms function in and are localized to the nucleus, cytoplasm, and mitochondria. The best understood function for PARG is in DNA damage repair. However, PARG also regulates gene splicing, transcriptional and epigenetic pathways (Bock FJ, Todorova TT, Chang P. Mol Cell 2015) (Le May, Litis et al. Mol Cell.2012) (Dahl, Maturi et al. Plos One, 2014) (Guastafierro, Catizone et al. Biochem J 2013) (Caiafa, Guastafierro et al. FASEB J 2009), cell division (Chang and Mitchison Nature 2004), the cytoplasmic stress response (Leung, Chang et al. Mol Cell 2011), and other cellular stresses. Modulation of both MAR and PAR levels have been shown to be effective treatments for multiple cancers. Inhibiting ADP-ribose synthesis through the use of PARP inhibitors can be used for the treatment of multiple cancer types. PARG inhibitors work by modulating Attorney Docket No.: 53238-0005WO1 cellular stress responses such as the DNA damage response (DDR) and the replicative stress response. DDR and replicative stress are very important cellular stress responses for cancers because they are a consequence of all cellular stress responses, thus many cancers have them. Cancers accumulate DNA damage due to the upregulation of cellular stress pathways and subsequent errors in DNA replication. In cancers, single-strand breaks (SSBs) are the most common type of DNA damage lesion and PARG together with PARP1 play important roles in single strand break repair (SSBR) and another repair mechanism called base excision repair (BER). PARP1 recognizes the break, binds to it, and rapidly synthesizes PAR onto itself (automodification) and histone proteins. Multiple DNA repair proteins, including a master regulator XRCC1, bind to and are recruited to the newly synthesized PAR and then repair the break (Mortusewicz, Fouquerel et al. Nucleic Acid Res.2011). Thus, the rapid increase in PAR acts as a key DNA repair signal. The signal initiated by PAR is transient as it becomes rapidly degraded by PARG. If PARG is absent or non-functional, PAR rapidly accumulates in the cancer cell and is toxic, resulting in cell death. When PARP1 is bound to or automodified by PAR, its catalytic activity is reduced and therefore PARG activity helps activate PARP1 and is an important regulator to keep the DNA damage repair signal “on” (Curtin and Szabo Mol Aspects Med.2013). PARG depletion by RNA interference (RNAi) has been shown to kill cancer cells and to result in tumor regression in multiple murine cancer models. Human and murine cells that are null or depleted for PARG display an increased sensitivity to DNA damaging agents demonstrating a general defect in DNA damage related stress responses upon inhibition or depletion of PARG. Other cancer relevant stress pathways have also been shown to be defective upon PARG knockdown, suggesting PARG is an attractive target for the treatment of multiple cancer types. In humans, PARG depletion kills lung, ovarian, breast, cervical, and pancreatic cancer cells in vitro. Xenograft models of these human cancers implanted into mice show tumor regression when PARG protein expression is knocked down. Together, these results demonstrate that PARG is an effective target for the treatment of multiple stress- dependent cancers, and potentially cancers where cellular stress responses are not obviously present. This invention seeks to provide cell permeable inhibitors of PARG. SUMMARY OF THE INVENTION The present invention is directed to a compound of Formula I: Attorney Docket No.: 53238-0005WO1 or a pharmaceutically acceptable salt constituent members are defined below. The present invention is further directed to a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. The present invention is further directed to a method of inhibiting the activity of PARG comprising contacting a compound of Formula I, or a pharmaceutically acceptable salt thereof, with PARG. The present invention is further directed to a method of treating a disease or disorder in a patient in need of treatment, where the disease or disorder is characterized by overexpression or increased activity of PARG, comprising administering to the patient a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. The present invention is further directed to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits PARG activity, such as a compound of Formula I, or a pharmaceutically acceptable salt thereof. The present disclosure also provides uses of the compounds described herein in the manufacture of a medicament for use in therapy. The present disclosure also provides the compounds described herein for use in therapy. DETAILED DESCRIPTION The present invention is directed to a compound of Formula I: I or a pharmaceutically acceptable salt thereof, wherein: Q is NH or CH2; A is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, or Cy-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6alkenyl, and C2-6alkynyl of A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 Attorney Docket No.: 53238-0005WO1 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd, B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), formula (h), formula (i), formula (j), or formula (k):

[0002] Attorney Docket No.: 53238-0005WO1 X2is N or CR2; X3is N or CR3; X4is N or CR4; X5is N or CR5; X6is N or CR6; X7is N or CR7; X8is N or CR8; X9is N or CR9; X10is N or CR10; X11is N or CR11; X12is N or CR12; X13is N or CR13; X14is N or CR14; X15is N or CR15; X16is N or CR16; X17is N or CR17; X18is N or CR18; X19is N or CR19; X20is N or CR20; X21is N or CR21; X22is N or CR22; X23is N or CR23; X24is N or CR24; X25is N or CR25; X26is N or CR26; X27is N or CR27; Attorney Docket No.: 53238-0005WO1 X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X1, X2, and X3are simultaneously N; wherein no more than two of X4, X5, and X6are simultaneously N; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X10, X11, and X12are simultaneously N; wherein no more than two of X13, X14, and X15are simultaneously N; wherein no more than two of X16, X17, and X18are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X22, X23, and X24are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; Attorney Docket No.: 53238-0005WO1 R1, R2, R4, R5, R7, R8, R10, R11, R13, R14, R16, R17, R19, R20, R22, R23, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4alkyl; R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, (CH2)qORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, membered heteroaryl, wherein said C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl of RX1, RX3, RX4, RX5, RX6, RX7, RY1, RY2, RY4, RY5, RY6, RY8, RZ1, RZ2, RZ3, RZ5, RZ7, and RZ8are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl, wherein the C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, Attorney Docket No.: 53238-0005WO1 NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C NRc3C NRc3S NRc3S NRc3S is 6 6 6 6 C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; Attorney Docket No.: 53238-0005WO1 or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc3and Rd3, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc4and Rd4, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, NHC1-4alkyl, N(C1-4alkyl)2, halo, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, and C1-6haloalkoxy; each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k), then A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl. Attorney Docket No.: 53238-0005WO1 The present invention is also directed to a compound of Formula I: or a pharmaceutically acceptable salt Q is NH or CH 2; A is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Cy, or Cy-C1-4alkyl-, wherein said C1-6alkyl, C2-6 alkenyl, and C2-6 alkynyl of A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd, B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), formula (h), formula (i), formula (j), or formula (k):

[0003] Attorney Docket No.: 53238-0005WO1 or X2is N or CR2; X3is N or CR3; X4is N or CR4; X5is N or CR5; X6is N or CR6; X7is N or CR7; X8is N or CR8; X9is N or CR9; X10is N or CR10; X11is N or CR11; X12is N or CR12; X13is N or CR13; X14is N or CR14; X15is N or CR15; X16is N or CR16; X17is N or CR17; X18is N or CR18; X19is N or CR19; Attorney Docket No.: 53238-0005WO1 X20is N or CR20; X21is N or CR21; X22is N or CR22; X23is N or CR23; X24is N or CR24; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X1, X2, and X3are simultaneously N; wherein no more than two of X4, X5, and X6are simultaneously N; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X10, X11, and X12are simultaneously N; wherein no more than two of X13, X14, and X15are simultaneously N; wherein no more than two of X16, X17, and X18are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X22, X23, and X24are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl, C1-4alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and Attorney Docket No.: 53238-0005WO1 S(O)2NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C Rb1, NRc1C ORa1, NRc1C NRc1Rd1, NRc1S Rb1, NRc1S2Rb1, are from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)qORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, membered heteroaryl, wherein said C1-6alkyl, C2-6alkenyl, and 5-membered heteroaryl of RX1, RX3, RX4, RX5, RX6, RX7, RY1, RY2, RY4, RY5, RY6, RY8, RZ1, RZ2, RZ3, RZ5, RZ7, and RZ8 halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; Attorney Docket No.: 53238-0005WO1 RW1, RW2, RW3, and RW4are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl, wherein the C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, aryl, C3- 7 10 4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; each Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, Attorney Docket No.: 53238-0005WO1 C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc3and Rd3, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl are Attorney Docket No.: 53238-0005WO1 each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, and C1-6haloalkoxy; each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4 alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k), then A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl. The present invention is also directed to a compound of Formula I: or a pharmaceutically acceptable salt Q is NH or CH2; A is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, or Cy-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6alkenyl, and C2-6alkynyl of A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd, B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), formula (h), formula (i), formula (j), or formula (k):

[0004] Attorney Docket No.: 53238-0005WO1 X1is N or CR1; X2is N or CR2; X3is N or CR3; X4is N or CR4; X5is N or CR5; X6is N or CR6; X7is N or CR7; X8is N or CR8; X9is N or CR9; X10is N or CR10; X11is N or CR11; X12is N or CR12; Attorney Docket No.: 53238-0005WO1 X13is N or CR13; X14is N or CR14; X15is N or CR15; X16is N or CR16; X17is N or CR17; X18is N or CR18; X19is N or CR19; X20is N or CR20; X21is N or CR21; X22is N or CR22; X23is N or CR23; X24is N or CR24; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X1, X2, and X3are simultaneously N; wherein no more than two of X4, X5, and X6are simultaneously N; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X10, X11, and X12are simultaneously N; wherein no more than two of X13, X14, and X15are simultaneously N; wherein no more than two of X16, X17, and X18are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X22, X23, and X24are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; Attorney Docket No.: 53238-0005WO1 each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C NRc1C NRc1C NRc1C C3-7 4 4 heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, membered heteroaryl, wherein said C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl of RX1, RX3, RX4, RX5, RX6, RX7, RY1, RY2, RY4, RY5, RY6, RY8, RZ1, RZ2, RZ3, RZ5, RZ7, and RZ8are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Attorney Docket No.: 53238-0005WO1 halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C NRc2Rd2, NRc2C NRc2Rd2, NRc2Rd2, NRc2C Rb2, NRc2C ORa2, each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, aryl, C3- 7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; each Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, Attorney Docket No.: 53238-0005WO1 SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc4and Rd4, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; Attorney Docket No.: 53238-0005WO1 each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 haloalkoxy; and each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; wherein when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k), then A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl. In some embodiments, Q is NH. In some embodiments, Q is CH2. In some embodiments, A is C1-6 alkyl. In some embodiments, A is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd. In some embodiments, A is C2-6alkenyl. In some embodiments, A is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 Attorney Docket No.: 53238-0005WO1 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd. In some embodiments, A is Cy. In some embodiments, A is Cy-C1-4 alkyl-. In some embodiments, A is selected from C3-7cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy. In some embodiments, A is C3-7cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy. In some embodiments, A is cyclopropyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy, wherein at least one RCyis C1-6 alkyl. In some embodiments, A is cyclopropyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy, wherein at least one RCyis methyl. In some embodiments, A is cyclopropyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy, wherein at least one RCyis CN. In some embodiments, A is cyclopropyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy, wherein the cyclopropyl is substituted with methyl and CN. In some embodiments, A is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy. In some embodiments, A is oxetanyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy. In some embodiments, A is oxetanyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy, In some embodiments, A is oxetanyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy, wherein at least one RCyis C1-6 alkyl, C1-6 haloalkyl, or CN. In some embodiments, A is oxetanyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy, wherein at least one RCyis methyl, fluoromethyl, or CN.

[0005] Attorney Docket No.: 53238-0005WO1 In some embodiments, A is selected , O , NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. , C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl- C1-4 alkyl, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4 Attorney Docket No.: 53238-0005WO1 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; n is an integer selected from 0, 1, 2, 3, and 4; and o is an integer selected from 0, 1, 2, and 3. In some embodiments, A is selected , O , C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; o is an integer selected from 0, 1, 2, and 3; and p is an integer selected from 0, 2, 3, 4, and 5. In some embodiments, A is selected ; and m is an integer selected from 0, 1, 2, 3, In some embodiments, A m is an integer selected 5. In some embodiments, A is selected Attorney Docket No.: 53238-0005WO1 m is an integer selected from 0, 1, 2, 3, 4, and 5. In some embodiments, A is selected , , In some embodiments, A is selected . In some embodiments, each RCyis C2-6 alkenyl, C2-6alkynyl, C2-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1. In some embodiments, each RCyis independently selected from halo, C2-6alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered Attorney Docket No.: 53238-0005WO1 heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1. In some embodiments, B is of formula (a): In some embodiments, In some embodiments, In some embodiments, B is of formula (d): Attorney Docket No.: 53238-0005WO1 (d). In some embodiments, B is of formula (e): In some embodiments, In some embodiments, In some embodiments, B In some embodiments, Attorney Docket No.: 53238-0005WO1 In some embodiments, B In some embodiments, B In some embodiments, B is of formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), formula (i), or formula (k): Attorney Docket No.: 53238-0005WO1 , formula (e), formula (f), formula (g), or formula (h):

[0006] Attorney Docket No.: 53238-0005WO1 , formula (c), formula (d), , , , In some embodiments, B is of formula (i) or formula (k): Attorney Docket No.: 53238-0005WO1 some , , formula (i), formula (j), or formula (k): In some embodiments, B is of formula (c), formula (g), formula (i), or formula (k):

[0007] Attorney Docket No.: 53238-0005WO1 some B is of formula (a): In some embodiments, X1is CR1. In some embodiments, is N. In some embodiments, X2is CR2. In some embodiments, X3is N. In some embodiments, X3is CR3. In some embodiments, X1is CR1; X2is CR2; and X3is CR3. In some embodiments, R1is H. In some embodiments, R1is halo. In some embodiments, R1is C1-4 alkyl. In some embodiments, R2is H. In some embodiments, R2is halo. In some embodiments, R2is C1-4 alkyl. In some embodiments, R3is H. In some embodiments, R3is halo. In some embodiments, R3is ORa2. In some embodiments, R3is NRc2Rd2. In some embodiments, R3is C6-10aryl. In some embodiments, R3is C6-10aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R3is C3-7 cycloalkyl. In some embodiments, R3is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from Attorney Docket No.: 53238-0005WO1 halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R3is 5-10 membered heteroaryl. In some embodiments, R3is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R3is 4-10 membered heterocycloalkyl. In some embodiments, R3is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, RX1is C1-6 alkyl. In some embodiments, RX1is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 Attorney Docket No.: 53238-0005WO1 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX1is 5-membered heteroaryl. In some embodiments, RX1is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY1is H. In some embodiments, RY1is halo. In some embodiments, RY1is C1-6 alkyl. In some embodiments, RY1is C1-6 alkyl optionally substituted with 1, 2, 3, substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY1is C2-6alkenyl. In some embodiments, RY1is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY1is 5-membered heteroaryl. In some embodiments, RY1is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 Attorney Docket No.: 53238-0005WO1 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ1is H. In some embodiments, RZ1is halo. In some embodiments, RZ1is C1-6alkyl. In some embodiments, RZ1is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ1is C2-6 alkenyl. In some embodiments, RZ1is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ1is 5-membered heteroaryl. In some embodiments, RZ1is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, B is of formula (b): In some embodiments, some X4is CR4. In some embodiments, X5is N. In some embodiments, X5is CR5. In some embodiments, X6is N. In some embodiments, X6is CR6. In some embodiments, X4is CR4; X5is CR5; and X6is CR6. In some embodiments, R4is H. In some embodiments, R4is halo. In some embodiments, R4is C1-4 alkyl. In some embodiments, R5is H. In some embodiments, R5is halo. In some embodiments, R5is C1-4 alkyl. In some embodiments, R6is H. In some embodiments, R6is halo. In some embodiments, R6is ORa2. In some embodiments, R6is NRc2Rd2. In some embodiments, R6is C6-10aryl. In some embodiments, R6is C6-10aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R6is 5-10 membered heteroaryl. In Attorney Docket No.: 53238-0005WO1 some embodiments, R6is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R6is 4-10 membered heterocycloalkyl. In some embodiments, R6is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX2is H. In some embodiments, RX2is halo. In some embodiments, RX2is C1-6 alkyl. In some embodiments, RX2is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX2is C2-6 alkenyl. In some embodiments, RX1is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX2is 5-membered heteroaryl. In some Attorney Docket No.: 53238-0005WO1 embodiments, RX2is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C NRc2C NRc2C NRc2C 6 some 6 with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY2is C2-6alkenyl. In some embodiments, RY2is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY2is 5-membered heteroaryl. In some embodiments, RY2is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, B is of formula (c): In some embodiments, X7some X7is CR7. In some embodiments, X8is N. In some embodiments, X8is CR8. In some embodiments, X9is N. In some embodiments, X9is CR9. In some embodiments, X7is CR7; X8is CR8; and X9is CR9. In some embodiments, R7is H. In some embodiments, R7is halo. In some embodiments, R7is C1-4alkyl. In some embodiments, R8is H. In some embodiments, R8is halo. In some embodiments, R8is C1-4alkyl. In some embodiments, R8is selected from H, fluoro, and bromo. In some embodiments, R9is H. In some embodiments, R9is halo. In some embodiments, R9is ORa2. In some embodiments, R9is NRc2Rd2. In some embodiments, R9is C6-10aryl. In some embodiments, R9is C6-10aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R9is C3-7 cycloalkyl. In some embodiments, R9is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, Attorney Docket No.: 53238-0005WO1 NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R9is 5-10 membered heteroaryl. In some embodiments, R9is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C NRc2C NRcC NRcC 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R9is selected from H and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.

[0008] Attorney Docket No.: 53238-0005WO1 , embodiments, RX3is C1-6 alkyl. In some embodiments, RX3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX3is C2-6alkenyl. In some embodiments, RX3is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX3is 5-membered heteroaryl. In some embodiments, RX3is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 Attorney Docket No.: 53238-0005WO1 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX3is selected from C1-6alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RX3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN. In some embodiments, RX3is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6 alkyl. In some embodiments, RX3is selected from , embodiments, RZ3is C1-6alkyl. In some embodiments, RZ3is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- Attorney Docket No.: 53238-0005WO1 C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ3is 5-membered heteroaryl. In some embodiments, RZ3is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ3is selected from H and halo. In some embodiments, RZ3is selected from H and chloro. In some embodiments, B is of formula (d): In some embodiments,10 10 X is CR . In some embodiments, X11is N. In some embodiments, X11is CR11. In some embodiments, X12is N. In some embodiments, X12is CR12. In some embodiments, X10is CR10; X11is CR11; and X12is CR12. In some embodiments, R10is H. In some embodiments, R10is halo. In some embodiments, R10is C1-4alkyl. In some embodiments, R11is H. In some embodiments, R11is halo. In some embodiments, R11is C1-4 alkyl. In some embodiments, R12is H. In some embodiments, R12is halo. In some embodiments, R12is ORa2. In some embodiments, R12is NRc2Rd2. In some embodiments, R12is C6-10aryl. In some embodiments, R12is C6-10aryl optionally substituted with 1, 2, 3, or 4 Attorney Docket No.: 53238-0005WO1 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R12is C3-7 cycloalkyl. In some embodiments, R12is C3-7cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R12is 5-10 membered heteroaryl. In some embodiments, R12is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, R12is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX4is H. In some embodiments, RX4is halo. In some embodiments, RX4is C1-6 alkyl. In some embodiments, RX4is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered Attorney Docket No.: 53238-0005WO1 heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX4is C2-6alkenyl. In some embodiments, RX4is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX4is 5-membered heteroaryl. In some embodiments, RX4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, RY4is C1-6alkyl. In some embodiments, RY4is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY4is C2-6alkenyl. In some embodiments, RY4is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, Attorney Docket No.: 53238-0005WO1 C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C NRc2Rd2, NRc2C NRc2Rd2, NRc2Rd2, NRc2C Rb2, NRc2C ORa2, substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, B is of formula (e): In some embodiments,13 13 X is CR . In some embodiments, X14is N. In some embodiments, X14is CR14. In some embodiments, X15is N. In some embodiments, X15is CR15. In some embodiments, X13is CR13; X14is CR14; and X15is CR15. In some embodiments, R13is H. In some embodiments, R13is halo. In some embodiments, R13is C1-4 alkyl. In some embodiments, R14is H. In some embodiments, R14is halo. In some embodiments, R14is C1-4 alkyl. In some embodiments, R15is H. In some embodiments, R15is halo. In some embodiments, R15is ORa2. In some embodiments, R15is NRc2Rd2. In some embodiments, R15 Attorney Docket No.: 53238-0005WO1 is C6-10 aryl. In some embodiments, R15is C6-10 aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R15is C3-7cycloalkyl. In some embodiments, R15is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R15is 5-10 membered heteroaryl. In some embodiments, R15is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, R15is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, RX5is C1-6alkyl. In some embodiments, RX5is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 Attorney Docket No.: 53238-0005WO1 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX5is C2-6 alkenyl. In some embodiments, RX5is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX5is 5-membered heteroaryl. In some embodiments, RX5is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY5is H. In some embodiments, RY5is halo. In some embodiments, RY5is C1-6 alkyl. In some embodiments, RY5is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY5is C2-6 alkenyl. In some embodiments, RY5is C2-6 Attorney Docket No.: 53238-0005WO1 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY5is 5-membered heteroaryl. In some embodiments, RY5is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, RZ5is C1-6alkyl. In some embodiments, RZ5is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ5is C2-6alkenyl. In some embodiments, RZ5is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ5is 5-membered heteroaryl. In some embodiments, RZ5is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C NRc2C NRc2C NRc2C In some embodiments, X16is N. In some embodiments, X16is CR16. In some embodiments, X17is N. In some embodiments, X17is CR17. In some embodiments, X18is N. In some embodiments, X18is CR18. In some embodiments, X16is CR16; X17is CR17; and X18is CR18. In some embodiments, R16is H. In some embodiments, R16is halo. In some embodiments, R16is C1-4alkyl. In some embodiments, R17is H. In some embodiments, R17is halo. In some embodiments, R17is C1-4alkyl. In some embodiments, R18is H. In some embodiments, R18is halo. In some embodiments, R18is ORa2. In some embodiments, R18is NRc2Rd2. In some embodiments, R18is C6-10 aryl. In some embodiments, R18is C6-10 aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and Attorney Docket No.: 53238-0005WO1 S(O)2NRc2Rd2. In some embodiments, R18is C3-7 cycloalkyl. In some embodiments, R18is C3-7cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R18is 5-10 membered heteroaryl. In some embodiments, R18is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R15is 4-10 membered heterocycloalkyl. In some embodiments, R15is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX6is H. In some embodiments, RX6is halo. In some embodiments, RX6is C1-6 alkyl. In some embodiments, RX6is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX6is C2-6 alkenyl. In some embodiments, RX6is C2-6 Attorney Docket No.: 53238-0005WO1 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX6is 5-membered heteroaryl. In some embodiments, RX6is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, RY6is C1-6alkyl. In some embodiments, RY6is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY6is C2-6alkenyl. In some embodiments, RY6is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY6is 5-membered heteroaryl. In some embodiments, RY6is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C NRc2C NRc2C NRc2C In some embodiments, X19is N. In some embodiments, X19is CR19. In some embodiments, X20is N. In some embodiments, X20is CR20. In some embodiments, X21is N. In some embodiments, X21is CR21. In some embodiments, X19is CR19; X20is CR20; and X21is CR21. In some embodiments, R19is H. In some embodiments, R19is halo. In some embodiments, R19is C1-4alkyl. In some embodiments, R20is H. In some embodiments, R20is halo. In some embodiments, R20is C1-4 alkyl. In some embodiments, R21is H. In some embodiments, R21is halo. In some embodiments, R21is ORa2. In some embodiments, R21is NRc2Rd2. In some embodiments, R21is C6-10 aryl. In some embodiments, R21is C6-10 aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R21is C3-7cycloalkyl. In some embodiments, R21is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C NRc2C NRc2C NRcC or 4 6 6 6 6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, R21is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX7is H. In some embodiments, RX7is halo. In some embodiments, RX7is C1-6alkyl. In some embodiments, RX7is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 S(O)2NRc2Rd2. In some embodiments, RX7is C2-6 alkenyl. In some embodiments, RX7is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, 2NRc2Rd2. In some embodiments, RX7is 5-membered heteroaryl. In some is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ7is H. In some embodiments, RZ7is halo. In some embodiments, RZ7is C1-6 alkyl. In some embodiments, RZ7is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ7is C2-6 alkenyl. In some embodiments, RZ7is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, Attorney Docket No.: 53238-0005WO1 NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RZ7is 5-membered heteroaryl. In some embodiments, RZ7is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, B is of formula (h): In some embodiments, X22is N. In some embodiments, X22is CR22. In some embodiments, X23is N. In some embodiments, X23is CR23. In some embodiments, X24is N. In some embodiments, X24is CR24. In some embodiments, X22is CR22; X23is CR23; and X24is CR24. In some embodiments, R22is H. In some embodiments, R22is halo. In some embodiments, R22is C1-4alkyl. In some embodiments, R23is H. In some embodiments, R23is halo. In some embodiments, R23is C1-4alkyl. In some embodiments, R24is H. In some embodiments, R24is halo. In some embodiments, R24is ORa2. In some embodiments, R24is NRc2Rd2. In some embodiments, R24is C6-10 aryl. In some embodiments, R24is C6-10 aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R24is C3-7cycloalkyl. In some embodiments, R24is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C NRc2C NRc2C NRcC or 4 6 6 6 6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, embodiments, R24is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RX8is H. In some embodiments, RX8is halo. In some embodiments, RX8is C1-6alkyl. In some embodiments, RX8is C1-6alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 S(O)2NRc2Rd2. In some embodiments, RX8is C2-6 alkenyl. In some embodiments, RX8is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, 2NRc2Rd2. In some embodiments, RX8is 5-membered heteroaryl. In some is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY8is H. In some embodiments, RY8is halo. In some embodiments, RY8is C1-6 alkyl. In some embodiments, RY8is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY8is C2-6 alkenyl. In some embodiments, RY8is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, Attorney Docket No.: 53238-0005WO1 NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, RY8is 5-membered heteroaryl. In some embodiments, RY8is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, B is of formula (i): In some embodiments, X25is N. In some embodiments, X25is CR25. In some embodiments, X26is N. In some embodiments, X26is CR26. In some embodiments, X27is N. In some embodiments, X27is CR27. In some embodiments, X25is CR25; X26is CR26; and X27is CR27. In some embodiments, R25is H. In some embodiments, R25is halo. In some embodiments, R25is C1-4 alkyl. In some embodiments, R26is H. In some embodiments, R26is halo. In some embodiments, R26is C1-4 alkyl. In some embodiments, R26is selected from H, fluoro, and bromo. In some embodiments, R27is H. In some embodiments, R27is halo. In some embodiments, R27is ORa2. In some embodiments, R27is NRc2Rd2. In some embodiments, R27is C6-10 aryl. In some embodiments, R27is C6-10 aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R27is C3-7 cycloalkyl. In some embodiments, R27is C3-7cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R27is 5-10 membered heteroaryl. In some embodiments, R27is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R27is 4-10 membered heterocycloalkyl. In some embodiments, R27is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, wherein said 4-10 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 , , optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, is C2-6 alkenyl. In some embodiments, RW1is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW1is 5-membered heteroaryl. In some embodiments, RW1is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW1is selected from C1-6alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW1is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN. In some embodiments, RW1is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6 alkyl. In some embodiments, RW1is selected from , Attorney Docket No.: 53238-0005WO1 In some embodiments, X28is CR28. In some embodiments, X29is N. In some embodiments, X29is CR29. In some embodiments, X30is N. In some embodiments, X30is CR30. In some embodiments, X28is CR28; X29is CR29; and X30is CR30. In some embodiments, R28is H. In some embodiments, R28is halo. In some embodiments, R28is C1-4 alkyl. In some embodiments, R29is H. In some embodiments, R29is halo. In some embodiments, R29is C1-4 alkyl. In some embodiments, R30is H. In some embodiments, R30is halo. In some embodiments, R30is ORa2. In some embodiments, R30is NRc2Rd2. In some embodiments, R30is C6-10 aryl. In some embodiments, R30is C6-10 aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, R30is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R30is 5-10 membered heteroaryl. In some embodiments, R30is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 Attorney Docket No.: 53238-0005WO1 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R30is 4-10 membered heterocycloalkyl. In some embodiments, R30is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, or some 6 In some embodiments, RW2is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW2is 5-membered heteroaryl. In some embodiments, RW2is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, B is of formula (k): In some embodiments, X31is N. In some embodiments, X31is CR31. In some embodiments, X32is N. In some embodiments, X32is CR32. In some embodiments, X33is N. In some embodiments, X33is CR33. In some embodiments, X31is CR31; X32is CR32; and X33is CR33. In some embodiments, R31is H. In some embodiments, R31is halo. In some embodiments, R31is C1-4 alkyl. Attorney Docket No.: 53238-0005WO1 In some embodiments, R32is H. In some embodiments, R32is halo. In some embodiments, R32is C1-4alkyl. In some embodiments, R32is selected from H, fluoro, and bromo. In some embodiments, R33is H. In some embodiments, R33is halo. In some embodiments, R33is ORa2. In some embodiments, R33is NRc2Rd2. In some embodiments, R33is C6-10aryl. In some embodiments, R33is C6-10aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, R33is C3- 7or from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R33is 5-10 membered heteroaryl. In some embodiments, R33is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R33is 4-10 membered heterocycloalkyl. In some embodiments, R33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R33is H. In some embodiments, R33is halo. In some embodiments, R33is ORa2. In some embodiments, R33is NRc2Rd2. In some embodiments, R33is C6-10 aryl. In some embodiments, R33is C6-10 aryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R33is C3-7cycloalkyl. In some embodiments, R33is C3-7 cycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R33is 5-10 membered heteroaryl. In some embodiments, R33is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R33is 4-10 membered heterocycloalkyl. In some embodiments, R33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, Attorney Docket No.: 53238-0005WO1 NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, R33is selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, ,

[0009] Attorney Docket No.: 53238-0005WO1 , 5

[0010] Attorney Docket No.: 53238-0005WO1 , , 5 Attorney Docket No.: 53238-0005WO1 , , 5 , Attorney Docket No.: 53238-0005WO1 , 7 6 6 7 and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3and RW4are selected from C1-6 alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3and RW4are C1-6alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN. In some embodiments, RW3and RW4are 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6alkyl. In some embodiments, at least one of RW3and RW4is 1,3,4-thiadiazolyl optionally substituted with 1 R’. In some embodiments, at least one of RW3and RW4is 1,3,4-thiadiazolyl optionally substituted with difluoromethyl, trifluoromethyl, or methanol. In some embodiments, RW3and RW4are selected from H, methyl, , . Attorney Docket No.: 53238-0005WO1 In some embodiments, RW3and RW4are selected from , 67are or RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3is H. In some embodiments, RW3is C1-6alkyl. In some embodiments, RW3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3is C2-6alkenyl. In some embodiments, RW3is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3is 5-membered heteroaryl. In some embodiments, RW2is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3is C1-6alkyl. In some embodiments, RW3is C1-6alkyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3is C2-6 alkenyl. In some embodiments, RW3is C2-6alkenyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3is 5-membered heteroaryl. In some embodiments, RW2is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. RW3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, NRc3Rd3, and CN.

[0011] Attorney Docket No.: 53238-0005WO1 In some embodiments, RW3is elected from H, methyl, , each optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN. In some embodiments, RW4is C1-6 alkyl. In some embodiments, RW4is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW4is C2-6alkenyl. In some embodiments, RW4is C2-6 alkenyl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW4is 5-membered heteroaryl. In some embodiments, RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6 alkyl. In some embodiments, RW3is elected from ; and . In some embodiments, RW3is selected from Attorney Docket No.: 53238-0005WO1 In some embodiments, B is of formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), formula (i), or formula (k): ; Attorney Docket No.: 53238-0005WO1 NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. In some embodiments, B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (h): Attorney Docket No.: 53238-0005WO1 , C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. In some embodiments, B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (h):

[0012] Attorney Docket No.: 53238-0005WO1 ; C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. In some embodiments, B is of formula (i), formula (j), or formula (k): , each RCy’is selected from from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. Attorney Docket No.: 53238-0005WO1 In some embodiments, B is of formula (i) or formula (k): , each is selected from from halo, CN, NO2, C(O) C(O) C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. In some embodiments, B is of formula (c), formula (g), formula (i), formula (j), or formula (k):

[0013] Attorney Docket No.: 53238-0005WO1 , C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. In some embodiments, B is of formula (c), formula (g), formula (i), formula (j), or formula (k): Attorney Docket No.: 53238-0005WO1 m , ; C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; o is an integer selected from 0, 1, 2, and 3; and p is an integer selected from 0, 2, 3, 4, and 5. In some embodiments, B is of formula (c), formula (g), formula (i), or formula (k): Attorney Docket No.: 53238-0005WO1 , C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula II-A: or a In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula II-B: Attorney Docket No.: 53238-0005WO1 or a pharmaceutically In some a Formula (I), or a pharmaceutically acceptable salt thereof, having Formula II-1: or a from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula III-A: or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula III-B: Attorney Docket No.: 53238-0005WO1 or a from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula IV-A: or a pharmaceutically In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula IV-B: R' N or a pharmaceutically In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula IV-1: Attorney Docket No.: 53238-0005WO1 or a from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula V-A: or a In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula V-B: or a pharmaceutically In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula V-1: Attorney Docket No.: 53238-0005WO1 or a n an from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VI-A: or a In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VI-B: or a pharmaceutically In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VI-1: Attorney Docket No.: 53238-0005WO1 or a from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VII-A: or a In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VII-B: or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VII-1: Attorney Docket No.: 53238-0005WO1 or a n an from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VIII-A: or a pharmaceutically In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VIII-B: R' N or a pharmaceutically In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula VIII-1: Attorney Docket No.: 53238-0005WO1 or a from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula IX-A: or a In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula IX-1: or a from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula X-A: Attorney Docket No.: 53238-0005WO1 or a In some a (I), or a pharmaceutically acceptable salt thereof, having Formula X-B: or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula X-1: or a selected from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula X-2: Attorney Docket No.: 53238-0005WO1 or a pharmaceutically selected from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula X-3: or a pharmaceutically acceptable salt thereof; wherein n is an integer selected from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula XI-A: or a Attorney Docket No.: 53238-0005WO1 In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula XI-1: or a n an selected from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula XII-A: or a In some embodiments, the compound is of Formula XII-A and Q is NH. In some embodiments, the compound is of Formula XII-A and RCyis selected from C1-6 alkyl and C1-6 haloalkyl. In some embodiments, the compound is of Formula XII-A and RCyis C1-6alkyl. In some embodiments, the compound is of Formula XII-A and RCyis C1-6haloalkyl. In some embodiments, the compound is of Formula XII-A and RCyis methyl. In some embodiments, the compound is of Formula XII-A and RCyis fluoromethyl. In some embodiments, the compound is of Formula XII-A and m is 1. In some embodiments, the compound is of Formula XII-A and X31is CR31. In some embodiments, the compound is of Formula XII-A and X31is CH. In some embodiments, the compound is of Formula XII-A and X32is CR32. In some embodiments, the compound is of Formula XII-A and X32is CH. In some embodiments, the compound is of Formula XII-A and X33is CR33. Attorney Docket No.: 53238-0005WO1 In some embodiments, the compound is of Formula XII-A and CR33is 4-10 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-A and CR33is 6-9 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-A and CR33is 6 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-A and CR33is 7 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-A and CR33is 9 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-A and CR33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl- C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, the compound is of Formula XII-A and CR33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, and CR33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, (CH2)mORa2, C(O)Rb2, and C(O)NRc2Rd2. In some embodiments, the compound is of Formula XII-A and RW3is C1-6alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, NRc3Rd3, and CN. In some embodiments, the compound is of Formula XII-A and RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6 alkyl. In some embodiments, the compound is of Formula XII-A and RW3and RW4are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, the compound is of Formula XII-A and RW3is selected from H, C1-6 alkyl, and C3-7 cycloalkyl, wherein the C1-6 alkyl and C3-7 cycloalkyl are optionally substituted with 1, 2, 3, or 4 R’; and RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. Attorney Docket No.: 53238-0005WO1 In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula XII-B: or a pharmaceutically In some embodiments, the compound is of Formula XII-B and Q is NH. In some embodiments, the compound is of Formula XII-B and RCyis selected from C1-6 alkyl and C1-6 haloalkyl. In some embodiments, the compound is of Formula XII-B and RCyis C1-6alkyl. In some embodiments, the compound is of Formula XII-B and RCyis C1-6haloalkyl. In some embodiments, the compound is of Formula XII-B and RCyis methyl. In some embodiments, the compound is of Formula XII-B and RCyis fluoromethyl. In some embodiments, the compound is of Formula XII-B and m is 1. In some embodiments, the compound is of Formula XII-B and X31is CR31. In some embodiments, the compound is of Formula XII-B and X31is CH. In some embodiments, the compound is of Formula XII-B and X32is CR32. In some embodiments, the compound is of Formula XII-B and X32is CH. In some embodiments, the compound is of Formula XII-B and X33is CR33. In some embodiments, the compound is of Formula XII-B and CR33is 4-10 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-B and CR33is 6-9 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-B and CR33is 6 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-B and CR33is 7 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-B and CR33is 9 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-B and CR33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl- Attorney Docket No.: 53238-0005WO1 C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, the compound is of Formula XII-B and CR33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6alkyl, C1-6haloalkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, the compound is of Formula XII-B and CR33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6alkyl, (CH2)mORa2, C(O)Rb2, and C(O)NRc2Rd2. In some embodiments, the compound is of Formula XII-B and RW3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, NRc3Rd3, and CN. In some embodiments, the compound is of Formula XII-B and R’ is C1-6 haloalkyl. In some embodiments, the compound is of Formula XII-B and RW3is selected from H, C1-6 alkyl, and C3-7 cycloalkyl, wherein the C1-6 alkyl and C3-7 cycloalkyl are optionally substituted with 1, 2, 3, or 4 R’; and R’ is C1-6 haloalkyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula XII-1: or a pharmaceutically acceptable salt thereof; wherein n is an integer selected from 0, 1, 2, 3, and 4. In some embodiments, the compound is of Formula XII-C and RCyis selected from C1-6 alkyl and C1-6 haloalkyl. In some embodiments, the compound is of Formula XII-A and RCyis C1-6alkyl. In some embodiments, the compound is of Formula XII-C and RCyis C1-6 Attorney Docket No.: 53238-0005WO1 haloalkyl. In some embodiments, the compound is of Formula XII-C and RCyis methyl. In some embodiments, the compound is of Formula XII-C and RCyis fluoromethyl. In some embodiments, the compound is of Formula XII-C and n is 0. In some embodiments, the compound is of Formula XII-C and R31is H. In some embodiments, the compound is of Formula XII-C and R32is H. In some embodiments, the compound is of Formula XII-C and R33is 4-10 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-C and R33is 6-9 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-C and R33is 6 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII- C and R33is 7 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-C and R33is 9 membered heterocycloalkyl. In some embodiments, the compound is of Formula XII-C and R33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, the compound is of Formula XII-C and R33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6alkyl, C1-6haloalkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. In some embodiments, the compound is of Formula XII-C and R33is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6alkyl, (CH2)mORa2, C(O)Rb2, and C(O)NRc2Rd2. In some embodiments, the compound is of Formula XII-C and RW3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, NRc3Rd3, and CN. In some embodiments, the compound is of Formula XII-C and RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6alkyl. In some embodiments, the compound is of Formula XII-C and RW3and RW4are each independently selected from H, C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered Attorney Docket No.: 53238-0005WO1 heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, the compound is of Formula XII-C and RW3is selected from H, C1-6alkyl, and C3-7cycloalkyl, wherein the C1-6alkyl and C3-7cycloalkyl are optionally substituted with 1, 2, 3, or 4 R’; and RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula XII-2: or a pharmaceutically acceptable salt thereof; wherein n is an integer selected from 0, 1, 2, 3, and 4. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having Formula XII-3: or a from 0, 1, 2, 3, and 4. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is an integer selected from 0, 2, 3, 4, and 5. Attorney Docket No.: 53238-0005WO1 In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, o is 0. In some embodiments, o is 1. In some embodiments, o is 2. In some embodiments, o is 3. In some embodiments, p is 0. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH or CH2; A is Cy or Cy-C1-4alkyl-; B is of formula (c), formula (g), formula (i), formula (j), or formula (k): X7is N or CR7; X8is N or CR8; X9is N or CR9; X19is N or CR19; X20is N or CR20; X21is N or CR21; X25is N or CR25; X26is N or CR26; Attorney Docket No.: 53238-0005WO1 X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1- 6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; R7, R8, R19, R20, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4 alkyl; R9, R21, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4- 10 membered heterocycloalkyl of R9, R21, R27, R30, and R33are each optionally substituted Attorney Docket No.: 53238-0005WO1 with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)qORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C NRc2Rd2, NRc2C NRc2Rd2, NRc2Rd2, NRc2C Rb2, NRcC ORa2, 6 heteroaryl of RX3, RX7, RZ3, and RZ7are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW2, RW3, and RW4are each independently selected from H, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, Attorney Docket No.: 53238-0005WO1 OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, is C6-10 aryl, C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; Attorney Docket No.: 53238-0005WO1 or Rc3and Rd3, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc4and Rd4, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, NHC1-4alkyl, N(C1-4alkyl)2, halo, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, and C1-6haloalkoxy; each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c), formula (g), or formula (k), then A is not 1- methylcyclopropyl, 1-cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH or CH2; A is Cy or Cy-C1-4alkyl-; B is of formula (c), formula (i), or formula (k): Attorney Docket No.: 53238-0005WO1 or X25is N or CR25; X26is N or CR26; X27is N or CR27; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C3-7cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, CN, NO2, ORa1, and NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, and NRc1Rd1; R7, R8, R25, R26, R31, and R32are each independently selected from H, halo, and C1-4 alkyl; R9, R27, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, (CH2)qORa2, ORa2, C(O)Rb2, C(O)NRc2Rd2, and C(O)ORa2; Attorney Docket No.: 53238-0005WO1 RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW2, RW3, and RW4are each independently selected from H, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa3, and NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, and NRc3Rd3; each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, and 4-10 membered heterocycloalkyl,, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, and 4-10 membered heterocycloalkyl of Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4alkyl, C1-6haloalkyl, CN, and ORa4; each Ra4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, amino, NHC1-4 alkyl, and N(C1-4alkyl)2; q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy; B is of formula (c), formula (i), or formula (k): Attorney Docket No.: 53238-0005WO1 X25is CR25; X26is CR26; X27is CR27; X31is CR31; X32is CR32; X33is CR33; each Cy is independently selected from C3-7 cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from C1-6alkyl, C1-6haloalkyl, and CN; R7, R8, R25, R26, R31, and R32are each independently selected from H and halo; R9, R27, and R33are each independently selected from H, halo, and 4-10 membered heterocycloalkyl, wherein 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6alkyl, (CH2)qORa2, C(O)Rb2, and C(O)NRc2Rd2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 haloalkyl; RW1, RW2, RW3, and RW4are each independently selected from H, C1-6 alkyl, C2-6 alkynyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkynyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkynyl, and C1-6 haloalkyl, wherein the C1-6alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from ORa3; Attorney Docket No.: 53238-0005WO1 each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C3-7cycloalkyl, and 4-10 membered heterocycloalkyl,, wherein said C1-6alkyl, C3-7 cycloalkyl, and 4-10 membered heterocycloalkyl of Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-6 haloalkyl and ORa4; each Ra4is independently selected from H, C1-6alkyl, and N(C1-4alkyl)2; q is 1; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4 alkyl-; B is of formula (c), formula (g), formula (i), formula (j), or formula (k): X7is N or CR7; X8is N or CR8; X9is N or CR9; X19is N or CR19; X20is N or CR20; Attorney Docket No.: 53238-0005WO1 X21is N or CR21; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, CN, NO2, ORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; R7, R8, R19, R20, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4alkyl; R9, R21, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4- Attorney Docket No.: 53238-0005WO1 10 membered heterocycloalkyl of R9, R21, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, CN, NO2, (CH2)mORa2, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, 5-membered optionally C2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW2, RW3, and RW4are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; each Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, , wherein said C1-6alkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, Attorney Docket No.: 53238-0005WO1 C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 haloalkoxy; and each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c), formula (g), or formula (k), then A is not 1- methylcyclopropyl, 1-cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4 alkyl-; B is a group of formula (c), formula (i) or formula (k): X9is N or CR9; X25is N or CR25; X26is N or CR26; X27is N or CR27; X31is N or CR31; X32is N or CR32; X33is N or CR33; Attorney Docket No.: 53238-0005WO1 wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C3-7cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, CN, NO2, ORa1, and NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, and NRc1Rd1; R7, R8, R25, R26, R31, and R32are each independently selected from H, halo, and C1-4 alkyl; R9, R27, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, (CH2)mORa2, ORa2, C(O)Rb2, C(O)NRc2Rd2, and C(O)ORa2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C3-7cycloalkyl, and 5-membered heteroaryl, wherein the C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa3, and NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, and NRc3Rd3; each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl; and Attorney Docket No.: 53238-0005WO1 q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy; B is a group of formula (c), formula (i), or formula (k): X9is CR9; X25is CR25; X26is CR26; X27is CR27; X31is CR31; X32is CR32; X33is CR33; each Cy is independently selected from C3-7 cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from C1-6 alkyl, C1-6 haloalkyl, and CN; R7, R8, R25, R26, R31, and R32are each independently selected from H and halo; R9, R27, and R33are each independently selected from H, halo, and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C(O)NRc2Rd2, (CH2)mORa2, and C(O)Rb2; Attorney Docket No.: 53238-0005WO1 RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 haloalkyl; RW1, RW3, and RW4are each independently selected from H, C1-6alkyl, C3-7cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkynyl, and C1-6 haloalkyl, wherein the C1-6alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from ORa3; each Rb2, Rc2, Rd2, and Ra3is independently selected from H and C1-6alkyl; and q is 1; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4 alkyl-;, B is of formula (c), formula (g), formula (i), formula (j), or formula (k):

[0014] Attorney Docket No.: 53238-0005WO1 X8is N or CR8; X9is N or CR9; X19is N or CR19; X20is N or CR20; X21is N or CR21; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, CN, NO2, ORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; Attorney Docket No.: 53238-0005WO1 R7, R8, R19, R20, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4alkyl; R9, R21, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4- 10 membered heterocycloalkyl of R9, R21, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, CN, NO2, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RX3, RX7, RZ3, and RZ7are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3, RX7, RZ3, and RZ7are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW2, RW3, and RW4are each independently selected from C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; Attorney Docket No.: 53238-0005WO1 each Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, , wherein said C1-6alkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C NRc4C C NRc4C S 66 6 6 6C2-6alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, and C1-6haloalkoxy; and each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4 alkyl, and CN; wherein when B is formula (c), formula (g), or formula (k), then A is not 1- methylcyclopropyl, 1-cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4alkyl-; B is a group of formula (c), formula (i) or formula (k): X9is N or CR9; X25is N or CR25; X26is N or CR26; X27is N or CR27; X31is N or CR31; Attorney Docket No.: 53238-0005WO1 X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C3-7cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, CN, NO2, ORa1, and NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, and NRc1Rd1; R7, R8, R25, R26, R31, and R32are each independently selected from H, halo, and C1-4 alkyl; R9, R27, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa2, C(O)Rb2, C(O)NRc2Rd2, and C(O)ORa2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW3, and RW4are each independently selected from C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa3, and NRc3Rd3, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, and C6-10 aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, and NRc3Rd3; Attorney Docket No.: 53238-0005WO1 each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy; B is a group of formula (c), formula (i), or formula (k): X9is CR9; X25is CR25; X26is CR26; X27is CR27; X31is CR31; X32is CR32; X33is CR33; each Cy is independently selected from C3-7 cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from C1-6 alkyl, C1-6 haloalkyl, and CN; R7, R8, R25, R26, R31, and R32are each independently selected from H and halo; R9, R27, and R33are each independently selected from H, halo, and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6alkyl, C(O)NRc2Rd2, and C(O)Rb2; Attorney Docket No.: 53238-0005WO1 RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 haloalkyl; RW1, RW3, and RW4are each independently selected from C1-6alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkynyl, and C1-6haloalkyl, wherein the C1-6 alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from ORa3; each Rb2, Rc2, Rd2, and Ra3is independently selected from H and C1-6 alkyl; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl. In some embodiments, when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k); A is Cy; and Cy is C3-7 cycloalkyl, then Cy is substituted with 0, 2, 3, 4, or 5 substituents independently selected from RCy. In some embodiments, when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k); and A is Cy; then Cy is C4-7 cycloalkyl substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy. In some embodiments, A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl. In some embodiments, A is not 1-methylcyclopropyl. In some embodiments, A is not 1-cyanocyclopropyl. In some embodiments, A is not 1- (fluoromethyl)cyclopropyl. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, selected from: {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; Attorney Docket No.: 53238-0005WO1 3-{3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonylamino}-3-oxetanecarbonitrile; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-(4-isobutyryl-1-piperazinyl)-6- (3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(4-isobutyryl-1-piperazinyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-(4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 1-(4-{1-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2- one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-3-(2,2,2-trifluoroethyl)-1,3-dihydro-1,3- benzimidazol-2-one; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-8-((3S,5S)-3,5-dimethylpiperazin-1-yl)- N-(3-methyloxetan-3-yl)imidazo[1,5-a]pyridine-6-sulfonamide; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; {7-[(R)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl- 2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; Attorney Docket No.: 53238-0005WO1 {7-(2,5-diazabicyclo[4.1.0]hept-2-yl)-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1- ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-1-cyclopropyl-3-[5-(difluoromethyl)-1,3,4- thiadiazol-2-yl]-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; N-(1-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-(3-methyl-3- oxetanylaminosulfonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-3-azepanyl)2- methylpropionamide; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-1- piperazinecarboxamide; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl- 3-oxetanyl)amine; N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}- 1,2,3,6-tetrahydro-1-pyridinecarboxamide; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-3-methyl-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-6-(3-methyl-3- oxetanylaminosulfonyl)-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-1,3-dihydro-1,3- benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-(2-oxa-7-aza-7- spiro[3.5]nonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3- oxetanyl]amine; Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-{4-[(1-methoxycyclopropyl)carbonyl]- 1-piperazinyl}-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3- benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3-azetidinyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 4-{(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl}-1-[5- (difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(R)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(S)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; 6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3- azetidinyl)carbonyl]-1-piperazinyl}-3-methyl-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- 1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(S)-4-isobutyryl-3-methyl-1-piperazinyl]-1,3-dihydro-2H-1,3- benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(2S,6S)-2,6-dimethyl-1,2,3,6- tetrahydro-4-pyridyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(R)-4-[(1- methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3- benzimidazol-2-one; 3-(2-aminoethyl)-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-(4-isobutyryl-1- piperazinyl)-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N,N- dimethylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1- piperazinyl]-3-methyl-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-3-methyl-1- piperazinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-{4-[(1- methoxycyclopropyl)carbonyl]-1-piperazinyl}-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-2H-1,3-benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-1-piperazinyl}- 1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-7-(1,2,3,6-tetrahydro-4- pyridyl)-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N- methylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(1-isobutyryl-1,2,3,6-tetrahydro-4-pyridyl)-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclobutyl)carbonyl]-1-piperazinyl}-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-methyl-4-(4-{[(R)-1-methyl-2-azetidinyl]carbonyl}-1- piperazinyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[4-(2-methoxy-2-methylpropionyl)-1-piperazinyl]-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(1-(1-(2-hydroxyethoxy)cyclopropane-1-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-oxo- 2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-(4-(1-ethoxycyclopropane-1- carbonyl)piperazin-1-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-4-((3S,5S)-3,5-dimethylpiperazin-1-yl)- N-(3-(fluoromethyl)oxetan-3-yl)-1H-benzo[d][1,2,3]triazole-6-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((3R,5R)-3,5-dimethylpiperazin-1-yl)- N-(3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-7-(4-(1-(2-fluoroethyl)-3- methoxyazetidine-3-carbonyl)piperazin-1-yl)-N-(3-(fluoromethyl)oxetan-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((3S,5R)-3,5-dimethylpiperazin-1-yl)- N-(3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(1-methoxycyclopropane-1-carbonyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((2S,6S)-2,6-dimethylmorpholino)-N- (3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(1-methoxycyclobutane-1-carbonyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(4-(3-methoxyoxetane-3-carbonyl)piperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; Attorney Docket No.: 53238-0005WO1 (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(2-methoxy-2-methylpropanoyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-(4-(1-(2- (dimethylamino)ethoxy)cyclopropane-1-carbonyl)piperazin-1-yl)-1-methyl-N-(3- methyloxetan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(4-(1-(methoxy-d3)cyclopropane-1-carbonyl)piperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N-dimethyl-3,6- dihydropyridine-1(2H)-carboxamide; 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N,2-trimethyl-3,6- dihydropyridine-1(2H)-carboxamide; and 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N,6-trimethyl-3,6- dihydropyridine-1(2H)-carboxamide. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, selected from: {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 3-{3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonylamino}-3-oxetanecarbonitrile; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; Attorney Docket No.: 53238-0005WO1 {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-(4-isobutyryl-1-piperazinyl)-6- (3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(4-isobutyryl-1-piperazinyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-(4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 1-(4-{1-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2- one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-3-(2,2,2-trifluoroethyl)-1,3-dihydro-1,3- benzimidazol-2-one; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-8-((3S,5S)-3,5-dimethylpiperazin-1-yl)- N-(3-methyloxetan-3-yl)imidazo[1,5-a]pyridine-6-sulfonamide; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; {7-[(R)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl- 2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-(2,5-diazabicyclo[4.1.0]hept-2-yl)-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1- ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; Attorney Docket No.: 53238-0005WO1 {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-1-cyclopropyl-3-[5-(difluoromethyl)-1,3,4- thiadiazol-2-yl]-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; N-(1-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-(3-methyl-3- oxetanylaminosulfonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-3-azepanyl)2- methylpropionamide; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-1- piperazinecarboxamide; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl- 3-oxetanyl)amine; N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}- 1,2,3,6-tetrahydro-1-pyridinecarboxamide; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-3-methyl-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-6-(3-methyl-3- oxetanylaminosulfonyl)-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-1,3-dihydro-1,3- benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-(2-oxa-7-aza-7- spiro[3.5]nonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3- oxetanyl]amine; Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-{4-[(1-methoxycyclopropyl)carbonyl]- 1-piperazinyl}-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3- benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3-azetidinyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 4-{(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl}-1-[5- (difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(R)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(S)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; 6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3- azetidinyl)carbonyl]-1-piperazinyl}-3-methyl-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- 1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(S)-4-isobutyryl-3-methyl-1-piperazinyl]-1,3-dihydro-2H-1,3- benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(2S,6S)-2,6-dimethyl-1,2,3,6- tetrahydro-4-pyridyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(R)-4-[(1- methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3- benzimidazol-2-one; 3-(2-aminoethyl)-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-(4-isobutyryl-1- piperazinyl)-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N,N- dimethylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1- piperazinyl]-3-methyl-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-3-methyl-1- piperazinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-{4-[(1- methoxycyclopropyl)carbonyl]-1-piperazinyl}-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-2H-1,3-benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-1-piperazinyl}- 1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-7-(1,2,3,6-tetrahydro-4- pyridyl)-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N- methylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(1-isobutyryl-1,2,3,6-tetrahydro-4-pyridyl)-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclobutyl)carbonyl]-1-piperazinyl}-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-methyl-4-(4-{[(R)-1-methyl-2-azetidinyl]carbonyl}-1- piperazinyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; and Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[4-(2-methoxy-2-methylpropionyl)-1-piperazinyl]-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, selected from: {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 3-{3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonylamino}-3-oxetanecarbonitrile; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-(4-isobutyryl-1-piperazinyl)-6- (3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(4-isobutyryl-1-piperazinyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-(4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 1-(4-{1-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2- one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-3-(2,2,2-trifluoroethyl)-1,3-dihydro-1,3- benzimidazol-2-one; and 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-8-((3S,5S)-3,5-dimethylpiperazin-1-yl)- N-(3-methyloxetan-3-yl)imidazo[1,5-a]pyridine-6-sulfonamide. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, selected from: 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; {7-[(R)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl- 2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-(2,5-diazabicyclo[4.1.0]hept-2-yl)-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1- ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-1-cyclopropyl-3-[5-(difluoromethyl)-1,3,4- thiadiazol-2-yl]-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; N-(1-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-(3-methyl-3- oxetanylaminosulfonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-3-azepanyl)2- methylpropionamide; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; Attorney Docket No.: 53238-0005WO1 N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-1- piperazinecarboxamide; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl- 3-oxetanyl)amine; N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}- 1,2,3,6-tetrahydro-1-pyridinecarboxamide; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-3-methyl-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-6-(3-methyl-3- oxetanylaminosulfonyl)-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-1,3-dihydro-1,3- benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-(2-oxa-7-aza-7- spiro[3.5]nonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3- oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-{4-[(1-methoxycyclopropyl)carbonyl]- 1-piperazinyl}-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3- benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3-azetidinyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 4-{(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl}-1-[5- (difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(R)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(S)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; 6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3- azetidinyl)carbonyl]-1-piperazinyl}-3-methyl-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- 1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(S)-4-isobutyryl-3-methyl-1-piperazinyl]-1,3-dihydro-2H-1,3- benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(2S,6S)-2,6-dimethyl-1,2,3,6- tetrahydro-4-pyridyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(R)-4-[(1- methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3- benzimidazol-2-one; 3-(2-aminoethyl)-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-(4-isobutyryl-1- piperazinyl)-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N,N- dimethylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1- piperazinyl]-3-methyl-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-3-methyl-1- piperazinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-{4-[(1- methoxycyclopropyl)carbonyl]-1-piperazinyl}-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-1-piperazinyl}- 1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-7-(1,2,3,6-tetrahydro-4- pyridyl)-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; Attorney Docket No.: 53238-0005WO1 {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N- methylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(1-isobutyryl-1,2,3,6-tetrahydro-4-pyridyl)-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclobutyl)carbonyl]-1-piperazinyl}-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-methyl-4-(4-{[(R)-1-methyl-2-azetidinyl]carbonyl}-1- piperazinyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; and 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[4-(2-methoxy-2-methylpropionyl)-1-piperazinyl]-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one; 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N,2-trimethyl-3,6- dihydropyridine-1(2H)-carboxamide; and 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N,6-trimethyl-3,6- dihydropyridine-1(2H)-carboxamide. In some embodiments, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, selected from: 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(1-(1-(2-hydroxyethoxy)cyclopropane-1-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-oxo- 2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide; Attorney Docket No.: 53238-0005WO1 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-(4-(1-ethoxycyclopropane-1- carbonyl)piperazin-1-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-4-((3S,5S)-3,5-dimethylpiperazin-1-yl)- N-(3-(fluoromethyl)oxetan-3-yl)-1H-benzo[d][1,2,3]triazole-6-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((3R,5R)-3,5-dimethylpiperazin-1-yl)- N-(3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-7-(4-(1-(2-fluoroethyl)-3- methoxyazetidine-3-carbonyl)piperazin-1-yl)-N-(3-(fluoromethyl)oxetan-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((3S,5R)-3,5-dimethylpiperazin-1-yl)- N-(3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(1-methoxycyclopropane-1-carbonyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((2S,6S)-2,6-dimethylmorpholino)-N- (3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(1-methoxycyclobutane-1-carbonyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(4-(3-methoxyoxetane-3-carbonyl)piperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(2-methoxy-2-methylpropanoyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-(4-(1-(2- (dimethylamino)ethoxy)cyclopropane-1-carbonyl)piperazin-1-yl)-1-methyl-N-(3- methyloxetan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide; Attorney Docket No.: 53238-0005WO1 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(4-(1-(methoxy-d3)cyclopropane-1-carbonyl)piperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; and 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N-dimethyl-3,6- dihydropyridine-1(2H)-carboxamide. It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination. At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term “C1-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl. At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency. For example, the term “pyridinyl,” “pyridyl,” or “a pyridine ring” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring. The term “n-membered,” where “n” is an integer, typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is “n”. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group. For compounds of the invention in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R. As used herein, the phrase “optionally substituted” means unsubstituted or substituted. Attorney Docket No.: 53238-0005WO1 As used herein, the term “substituted” means that a hydrogen atom is replaced by a non-hydrogen group. It is to be understood that substitution at a given atom is limited by valency. As used herein, the term “C1-j,” where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, C1-6alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms. As used herein, the term “alkyl,” employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. In some embodiments, the alkyl group contains 1 to 7, 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methyl-1-butyl, 3- pentyl, n-hexyl, 1,2,2-trimethylpropyl, n-heptyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl. As used herein, “alkenyl,” employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon double bonds. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like. As used herein, “alkynyl,” employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon triple bonds. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms. As used herein, “halo” or “halogen”, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl. As used herein, the term “haloalkyl,” employed alone or in combination with other terms, refers to an alkyl group having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, and the like. As used herein, the term “alkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-alkyl. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. Attorney Docket No.: 53238-0005WO1 As used herein, “haloalkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl). In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. An example haloalkoxy group is -OCF3. As used herein, “amino,” employed alone or in combination with other terms, refers to NH2. As used herein, the term “cycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term “cycloalkyl” also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-1-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3-7monocyclic cycloalkyl group. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. As used herein, the term “heterocycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of heterocycloalkyl Attorney Docket No.: 53238-0005WO1 are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-1-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [1,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or about 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 2 to 20 carbon atoms, 2 to 15 carbon atoms, 2 to 10 carbon atoms, or about 2 to 8 carbon atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl portion is a C2-7 monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, tetrahydropyran ring, tetrahydropyridine, azetidine ring, or tetrahydrofuran ring. As used herein, the term “aryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., a fused ring system) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl. As used herein, the term “heteroaryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., a fused ring system) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or a bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to Attorney Docket No.: 53238-0005WO1 form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved. In some embodiments, the heteroaryl group has from 3 to 10 carbon atoms, from 3 to 8 carbon atoms, from 3 to 5 carbon atoms, from 1 to 5 carbon atoms, or from 5 to 10 carbon atoms. In some embodiments, the heteroaryl group contains 3 to 14, 4 to 12, 4 to 8, 9 to 10, or 5 to 6 ring- forming atoms. In some embodiments, the heteroaryl group has 1 to 4, 1 to 3, or 1 to 2 heteroatoms. The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention may be isolated as a mixture of isomers or as separated isomeric forms. Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone – enol pairs, amide - imidic acid pairs, lactam – lactim pairs, enamine – imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. An example of tautomeric forms, pyridazin-3(2H)-one and pyridazin-3-ol, is depicted below: . Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic Attorney Docket No.: 53238-0005WO1 number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, the compounds of the invention include at least one deuterium atom. The term, “compound,” as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted, unless otherwise specified. All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated. In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art. As used herein, and unless otherwise specified, the term "about", when used in connection with a numeric value or range of values which is provided to describe a particular solid form (e.g., a specific temperature or temperature range, such as describing a melting, dehydration, or glass transition; a mass change, such as a mass change as a function of temperature or humidity; a solvent or water content, in terms of, for example, mass or a percentage; or a peak position, such as in analysis by, for example,13C NMR, DSC, TGA and XRPD), indicate that the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art while still describing the particular solid form. The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically Attorney Docket No.: 53238-0005WO1 acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p.1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. Synthesis Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes. The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan. Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety. Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g.,1H or13C), infrared spectroscopy, spectrophotometry Attorney Docket No.: 53238-0005WO1 (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography. The expressions, “ambient temperature,” “room temperature,” and “RT”, as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 ºC to about 30 ºC. Compounds of Formula I can be prepared according to numerous preparatory routes known in the literature. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below. Unless noted otherwise, all substituents are as defined herein. In the process depicted in Scheme 1, an appropriately substituted, aryl fluoride- containing compound of Formula (1-1) is substituted with amine compound (1-2) in the presence of a base and heat to form the aryl compound of Formula (1-3). The compound of Formula (1-3) is substituted with amine compound (1-4) in the presence of a base and heat to form the nitro compound of Formula (1-5). The nitro compound of Formula (1-5) is reduced in the presence of iron and acid to form amine compound of Formula (1-6). The compound of Formula (1-6) is cyclized in the presence of sodium nitrite and acid to form triazole compound of Formula (1-7). The compound of Formula (1-7) is reacted with a palladium catalyst like palladium acetate, K2SO5and then N-fluorobenzenesulfonimide to form sulfonyl fluoride compound of Formula (1-8). The compound of Formula (1-8) is substituted with amine compound of Formula (1-9) to form sulfonamide compound of Formula (1-9). Scheme 1

[0015] Attorney Docket No.: 53238-0005WO1 wherein: Ring C is an N-containing 5-10 membered heteroaryl or N-containing 4-10 membered heterocycloalkyl, wherein said 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; and Ring D is 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’. In the process depicted in Scheme 1, an appropriately substituted, aryl fluoride- containing compound of Formula (2-1) is substituted with amine compound (2-2) in the presence of a base to form the aryl compound of Formula (2-3). The compound of Formula Attorney Docket No.: 53238-0005WO1 (2-3) is reduced to form amine compound of Formula (2-4). The compound of Formula (2-4) is cyclized with 1,1'-carbonyldiimidazole to form benzimidazole compound of Formula (2-5). The compound of Formula (2-5) is substituted with a compound of Formula (2-6) in the presence of base and heat to form the compound of Formula (2-7). The compound of Formula (2-7) is substituted with chlorosulfonic acid to form sulfonyl chloride compound of Formula (2-8). The compound of Formula (2-8) is substituted with a compound of Formula (2-9) in the presense of base to form sulfonamide compound of Formula (2-10). Scheme 2 Ring D is 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; and LG is a leaving group, such as halo. In the process depicted in Scheme 3, an appropriately substituted, aryl fluoride- containing compound of Formula (3-1) is substituted with an appropriately substituted heterocycloalkyl (3-2, e.g., piperidinyl) in the presence of a base to form the aryl compound of Formula (3-3). The aryl fluoride containing-compound of Formula (3-3) is substituted with Attorney Docket No.: 53238-0005WO1 amine compound (3-4) to form aryl compound of Formula (3-5). The compound of Formula (3-5) is reduced and cyclized to form the compound of Formula (3-6). The compound of Formula (3-6) is substituted with a compound of Formula (3-7) in the presence of a base to form compound of Formula (3-8). The compound of Formula (3-8) is reacted with a palladium catalyst like palladium acetate, K2SO5 and then N-fluorobenzenesulfonimide to form sulfonyl fluoride compound of Formula (3-9). The compound of Formula (3-9) is substituted with amine compound of Formula (3-10) to form sulfonamide compound of Formula (3-11). Scheme 3 heterocycloalkyl, wherein said 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2. Attorney Docket No.: 53238-0005WO1 In the process depicted in Scheme 4, an appropriately substituted, aryl fluoride- containing compound of Formula (4-1) is substituted with an amine compound of Formula (4-2) to form aryl compound of Formula (4-3). The compound of Formula (4-3) is cyclized to form the aryl compound of Formula (4-4). The compound of Formula (4-4) is substituted with a compound of Formula (4-5) to form benzimidazolone compound of Formula (4-6). The compound of Formula (4-6) is reacted with a palladium catalyst like palladium acetate, K2SO5 and then N-fluorobenzenesulfonimide to form sulfonyl fluoride compound of Formula (4-7). The compound of Formula (4-7) is substituted with amine compound of Formula (4-8) to form sulfonamide compound of Formula (4-9). The compound of Formula (4-9) is substituted with borate compound of Formula (4-10, e.g., a tetrahydropyridinyl substituted with a borate moiety) in the presence of a palladium catalyst and base to form sulfonamide compound of Formula (4-11). Scheme 4 heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4- 10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 Attorney Docket No.: 53238-0005WO1 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)qORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; and each RBXis independently selected from H and C1-6alkyl or the two RBXs can be joined in ring and optionally substituted. Methods of Use Compounds of the invention can inhibit the activity of PARG. For example, the compounds of the invention can be used to inhibit activity of PARG in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of a compound of the invention to the cell, individual, or patient. In some embodiments, the PARG is PARG1. As PARG inhibitors, the compounds of the invention are useful in the treatment of various diseases or disorders associated with abnormal expression or activity of PARG and diseases and disorders sensitive to the accumulation of ADP-ribose that results from treatment with PARG inhibitors. For example, the compounds of the invention are useful in the treatment of cancer. In some embodiments, the cancer is a cellular stress-dependent cancer. In some embodiments, the cancer exhibits cancer dependent transcriptional gene misregulation. In some embodiments, the cancer is selected from lung cancer, colon cancer, breast cancer, ovarian cancer, gastric cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, skin cancer, bladder cancer, esophageal cancer, head and neck cancer, kidney cancer, rectal cancer, stomach cancer, thyroid cancer, uterine cancer, mantle cell lymphoma, and renal cell carcinoma. As used herein, the term “cell” is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal. As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” PARG or Attorney Docket No.: 53238-0005WO1 “contacting” a cell with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having PARG, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing PARG. As used herein, the term “individual” or “patient,” used interchangeably, refers to mammals, and particularly humans. Typically, the individual or patient is in need of treatment. As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. As used herein the term “treating” or “treatment” refers to 1) inhibiting the disease in an individual who is experiencing or displaying the pathology or symptomatology of the disease (i.e., arresting further development of the pathology and / or symptomatology), or 2) ameliorating the disease in an individual who is experiencing or displaying the pathology or symptomatology of the disease (i.e., reversing the pathology and / or symptomatology). As used herein the term “preventing” or “prevention” refers to preventing the disease in an individual who may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease. Combination Therapy One or more additional pharmaceutical agents or treatment methods such as, for example, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, immunotherapies, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.), and / or kinase (tyrosine or serine / threonine), epigenetic or signal transduction inhibitors can be used in combination with the compounds of the present invention. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms. Suitable agents for use in combination with the compounds of the present invention for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy. Compounds of this invention may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors. Suitable examples are anti-estrogen agents including but not limited to tamoxifen and Attorney Docket No.: 53238-0005WO1 toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant). Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds of the present invention. These include anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g. abiraterone). Angiogenesis inhibitors may be efficacious in some tumors in combination with the compounds of the present invention. These include antibodies against VEGF or VEGFR, or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib Suitable chemotherapeutic or other anti-cancer agents for use in combination with the compounds of the present invention include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (CytoxanTM), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethio- phosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide. Additional anti-cancer agent(s) for use in combination with the compounds of the present invention include DNA damage or cell cycle check point inhibitors, including ATR, ATM, Wee1, CHK1, CHK2, Pol Theta inhibitors. Other anti-cancer agent(s) for use in combination with the compounds of the present invention include antibody therapeutics to checkpoint or costimulatory molecules such as CTLA-4, PD-1, PD-L1 or 4-1BB, respectively, or antibodies to cytokines (IL-10, TGF-β, etc.). Exemplary cancer immunotherapy antibodies include pembrolizumab, ipilimumab, nivolumab, atezolizumab and durvalumab. Additional anti-cancer agent(s) for use in combination with the compounds of the present invention include antibody therapeutics directed to surface molecules of hematological cancers such as ofatumumab, rituximab, and alemtuzumab. Attorney Docket No.: 53238-0005WO1 Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety. Pharmaceutical Formulations and Dosage Forms When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions. A pharmaceutical composition refers to a combination of a compound of the invention, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be oral, topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, or parenteral. This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. The compositions can be formulated in a unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Attorney Docket No.: 53238-0005WO1 The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above. The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure Attorney Docket No.: 53238-0005WO1 breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner. The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like. The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. The compounds of the invention can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti- viral agents, anti-cancer agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like. EXAMPLES Definitions: ACN (acetonitrile); AcOH (acetic acid); d (doublet); DCM (dichloromethane); DIBAl-H (diisobutylaluminium hydride); DIEA (N,N-diisopropylethylamine); DMF (N,N- Attorney Docket No.: 53238-0005WO1 dimethylformamide); DMSO (dimethylsulfoxide); DMSO-d6 (deuterated dimethylsulfoxide); EA (ethyl acetate); equiv (equivalents); ESI (electrospray ionization); EtOAc (ethyl acetate); EtOH (ethanol); g (gram); h (hour); HCl (hydrochloric acid); HOBT (hydroxybenzotriazole);1H NMR (proton nuclear magnetic resonance); Hz (hertz); IPA (iso-propyl alcohol); L (liter); LCMS (liquid chromatography-mass spectrometry); LiCl (lithium chloride); LiOH (lithium hydroxide); M (molar); m (multiplet); MeOH (methanol); mg (milligrams); MHz (megahertz); min (minutes); mL (milliliters), mmol (millimoles); m / z (mass per charge); NBS (N-bromo succinimide); NFSI (N-fluorodi(benzenesulfonyl)amine); nm (nanometers); Pd- PEPPSI-IPent (dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3- chloropyridyl)palladium(II)); PE (petroleum ether); PPh3(triphenylphosphine); ppm (parts per million); prep-HPLC (preparative high-performance liquid chromatography); q (quartet); RT (room temperature); RT (retention time); s (singlet); TEA (triethylamine); TEAB (tetraethylammonium bromide); THF (tetrahydrofuran); t (triplet); TLC (thin layer chromatography); UV (ultraviolet); and v / v (volume / volume). Example 1: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-N-(3-methyloxetan-3-yl)-7-[4-(2- methylpropanoyl)piperazin-1-yl]-1,2,3-benzotriazole-5-sulfonamide Step 1: N-(5-bromo-3-fluoro-2-nitrophenyl)-5-(difluoromethyl)-1,3,4- thiadiazol-2-amine. To a mixture of 5-bromo-1,3-difluoro-2-nitrobenzene (4 g, 16.808 mmol, 1 equiv), 5- (difluoromethyl)-1,3,4-thiadiazol-2-amine (3.05 g, 20.17 mmol, 1.2 equiv) and Cs2CO3(6.57 g, 20.17 mmol, 1.2 equiv) in DMF (40 mL) was stirred at 100 °C for 16 h. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (200 mL). The resulting mixture was extracted with EA (3×150 mL). The combined organic layers were washed with brine (2 × 200 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to Attorney Docket No.: 53238-0005WO1 afford N-(5-bromo-3-fluoro-2-nitrophenyl)-5-(difluoromethyl)-1,3,4-thiadiazol-2-amine (2.2 g, 31.91%) as a yellow solid. LCMS (ES, m / z): 372, 374 [M+H]+Step 2: 1-[4-(5-bromo-3-{[5-(difluoromethyl)-1,3,4- thiadiazol-2-yl] amino}-2-nitrophenyl) piperazin-1-yl]-2-methylpropan-1-one. A mixture of 1-[4-(5-bromo-3-fluoro-2-nitrophenyl)piperazin-1-yl]-2-methylpropan- 1-one (2 g, 5.345 mmol, 1 equiv), 5-(difluoromethyl)-1,3,4-thiadiazol-2-amine (0.97 g, 6.414 mmol, 1.2 equiv) and Cs2CO3(5.22 g, 16.035 mmol, 3 equiv) in THF (20 mL) was stirred at 70 °C for 16 h. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (150 mL). The resulting mixture was extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (2 × 200 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-[4-(5-bromo-3-{[5-(difluoromethyl)- 1,3,4- thiadiazol-2-yl] amino}-2-nitrophenyl) piperazin-1-yl]-2-methylpropan-1-one (800 mg, 26.66%) as a dark yellow solid. LCMS (ES, m / z): 505, 507[M+H]+Step 3: 1-[4-(2-amino-5-bromo-3-{[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl] amino} phenyl) piperazin-1-yl]-2-methylpropan-1-one. To a stirred mixture of 1-[4-(5-bromo-3-{[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl] amino}-2-nitrophenyl) piperazin-1-yl]-2-methylpropan-1-one (800 mg, 1.583 mmol, 1 equiv) in EA (10 mL) was added HOAc (3 mL), Fe powder (397.84 mg, 7.124 mmol, 4 equiv) and H2O (3 mL). The resulting mixture was stirred for 2 h at 70 °C. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with H2O (100 mL). The resulting mixture was extracted with EA (3 × 80 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-[4-(2-amino-5-bromo-3-{[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl] amino} phenyl) piperazin-1-yl]-2-methylpropan-1-one (600 mg, 71.76%) as a brown solid. LCMS (ES, m / z): 475, 477 [M+H]+Step 4: 1-(4-{6-bromo-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1,2,3- benzotriazol-4- yl}piperazin-1-yl)-2-methylpropan-1-one. Attorney Docket No.: 53238-0005WO1 To a stirred solution of 1-[4-(2-amino-5-bromo-3-{[5-(difluoromethyl)-1,3,4- thiadiazol-2-yl] amino} phenyl) piperazin-1-yl]-2-methylpropan-1-one (600 mg, 1.262 mmol, 1 equiv) in conc. HCl (6 mL) was slowly added NaNO2 (104.50 mg, 1.514 mmol, 1.2 equiv) at 0 °C. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored by LCMS. The mixture was basified to pH 10 with NaOH (1M). The resulting mixture was extracted with EA (3×80 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-(4-{6-bromo-1-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1,2,3- benzotriazol-4-yl}piperazin-1-yl)-2-methylpropan-1-one (400 mg, 70.37%) as a yellow solid. LCMS (ES, m / z): 486, 488 [M+H]+Step 5: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[4-(2-methylpropanoyl)piperazin-1- yl]-1,2,3- benzotriazole-5-sulfonyl fluoride. To a stirred mixture of 1-(4-{6-bromo-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1,2,3- benzotriazol-4-yl}piperazin-1-yl)-2-methylpropan-1-one (600 mg, 1.234 mmol, 1 equiv) in DMSO (10 mL) was added dipotassium sulfinosulfonate (548.56 mg, 2.468 mmol, 2 equiv), tetraethylazanium bromide (285.20 mg, 1.357 mmol, 1.1 equiv), sodium formate (251.71 mg, 3.702 mmol, 3 equiv), PPh3(97.08 mg, 0.370 mmol, 0.3 equiv), phen (66.70 mg, 0.370 mmol, 0.3 equiv) and palladium acetate (27.70 mg, 0.123 mmol, 0.1 equiv) at room temperature. The resulting mixture was stirred for 4 h at 70 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. To the above mixture was added the solution of NFSI (778.05 mg, 2.468 mmol, 2 equiv) in THF (2 mL) dropwise at room temperature. The resulting mixture was stirred for additional 2 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was diluted with H2O (100 mL). The resulting mixture was extracted with EA (3×80 mL). The combined organic layers were washed with brine (2×100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-7-[4-(2-methylpropanoyl)piperazin-1-yl]-1,2,3- benzotriazole-5-sulfonyl fluoride (300 mg, 50%) as a yellow solid. LCMS (ES, m / z): 490 [M+H]+Step 6: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-N-(3-methyloxetan-3-yl)-7-[4-(2- methylpropanoyl)piperazin-1-yl]-1,2,3-benzotriazole-5-sulfonamide. Attorney Docket No.: 53238-0005WO1 To a stirred solution of 1-(4-{6-bromo-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl] - 1,2,3-benzotriazol-4-yl}piperazin-1-yl)-2-methylpropan-1-one (100 mg, 0.206 mmol, 1 equiv) and 3-methyloxetan-3-amine (35.83 mg, 0.412 mmol, 2 equiv) in DMSO (2 mL) were added HOBT (2.78 mg, 0.021 mmol, 0.1 equiv), [(dimethylsilyl)oxy] dimethylsilane (55.24 mg, 0.412 mmol, 2 equiv) and DIEA (132.88 mg, 1.030 mmol, 5 equiv) in portions at room temperature. The reaction was stirred at room temperature for 2 h. The reaction was monitored by LCMS. The resulting mixture was diluted with H2O (30 mL). The resulting mixture was extracted with EA (3×20 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by prep-HPLC with the following conditions: (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water(10mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min mL / min; Gradient: 32%B to 62%B in 7 min; Wave Length: 254nm / 220nm nm; RT1(min): 6.22) to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-N-(3-methyloxetan-3-yl)-7-[4-(2- methylpropanoyl)piperazin-1-yl]-1,2,3-benzotriazole-5-sulfonamide (45.3 mg, 39.26%) as a yellow solid. LCMS (ES, m / z): 557.15[M+H]+.1H NMR (300 MHz, Chloroform-d) δ=8.40 (s, 1H), 7.29-6.89 (m, 2H), 5.75 (s, 1H), 4.77 (d, J=6.3 Hz, 2H), 4.36 (d, J=6.6 Hz, 2H), 4.11- 3.78 (m, 8H), 2.95-2.78 (m, 1H), 1.65 (s, 3H), 1.19 (d, J=6.9 Hz, 6H). Example 2: 3-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-N-(3-methyloxetan-3-yl)-7-(4- propanoylpiperazin-1-yl)-1,2,3-benzotriazole-5-sulfonamide Step 1: 1-[4-(5-bromo-3-fluoro-2-nitrophenyl)piperazin-1-yl]-2-methylpropan-1-one. A solution of 5-bromo-1,3-difluoro-2-nitrobenzene (4 g, 16.808 mmol, 1 equiv), 2- methyl-1-(piperazin-1-yl)propan-1-one (2.63 g, 16.808 mmol, 1 equiv) and Cs2CO3(16.43 g, 50.424 mmol, 3 equiv) in DMF (40 mL) was stirred for overnight at 100 °C .The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The Attorney Docket No.: 53238-0005WO1 resulting mixture was diluted with water (120 mL). The resulting mixture was extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (3×100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-[4-(5-bromo-3-fluoro-2-nitrophenyl)piperazin-1-yl]-2- methylpropan-1-one (5 g, 71.55%) as a yellow solid. LCMS (ESI, m / z): 374, 376[M+H]+. Step 2: ethyl 5-({5-bromo-3-[4-(2-methylpropanoyl)piperazin-1-yl]-2-nitrophenyl}amino)- 1,3,4-thiadiazole-2-carboxylate. A solution of 1-[4-(5-bromo-3-fluoro-2-nitrophenyl)piperazin-1-yl]-2-methylpropan- 1-one (4 g, 10.689 mmol, 1 equiv) ,ethyl 5-amino-1,3,4-thiadiazole-2-carboxylate (1.67 g, 9.620 mmol, 0.9 equiv) and Cs2CO3(10.45 g, 32.067 mmol, 3 equiv) in DMF (40 mL) was stirred for overnight at 70 °C. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water (150 mL). The resulting mixture was extracted with EtOAc (3 x 120 mL). The combined organic layers were washed with brine (2 x 150 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford ethyl 5-({5-bromo-3-[4-(2-methylpropanoyl)piperazin-1-yl]-2-nitrophenyl}amino)- 1,3,4-thiadiazole-2-carboxylate (3.8 g, 60.67%) as a yellow solid. LCMS (ESI, m / z): 527, 529 [M+H]+. Step 3: ethyl 5-({2-amino-5-bromo-3-[4-(2-methylpropanoyl)piperazin-1-yl] phenyl}amino)- 1,3,4-thiadiazole-2-carboxylate. A mixture of ethyl 5-({5-bromo-3-[4-(2-methylpropanoyl)piperazin-1-yl]-2- nitrophenyl}amino)-1,3,4-thiadiazole-2-carboxylate (4.5 g, 8.533 mmol, 1 equiv) and Fe powder (1.91 g, 34.132 mmol, 4 equiv) in a mixed solvent of EA (40 mL), H2O (10 mL) and AcOH (3 mL) was stirred for 2 h at 70 °C. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The resulting mixture was filtered, the filter cake was washed with EtOAc (3 x 10 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM / MeOH (10:1) to afford ethyl 5-({2-amino-5-bromo-3-[4-(2- methylpropanoyl)piperazin-1-yl] phenyl}amino)-1,3,4-thiadiazole-2-carboxylate (2 g, 42.41%) as a yellow solid. LCMS (ESI, m / z): 497, 499 [M+H]+. Attorney Docket No.: 53238-0005WO1 Step 4: ethyl 5-{6-bromo-4-[4-(2-methylpropanoyl)piperazin-1-yl]-1,2,3-benzotriazol-1-yl}- 1,3,4-thiadiazole-2-carboxylate. To a stirred solution of ethyl 5-({2-amino-5-bromo-3-[4-(2- methylpropanoyl)piperazin-1-yl]phenyl} amino)-1,3,4-thiadiazole-2-carboxylate (2 g, 4.021 mmol, 1 equiv) in HCl (20 mL, 2M) was added NaNO2(0.35 g, 5.026 mmol, 1.25 equiv) in portions at 0 °C. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was diluted with water (50 mL). The mixture was extracted with EtOAc (3 x 80 mL). The combined organic layers were washed with brine (2 x 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford ethyl 5-{6-bromo-4-[4-(2- methylpropanoyl)piperazin-1-yl]-1,2,3-benzotriazol-1-yl}-1,3,4-thiadiazole-2-carboxylate (700 mg, 30.82%) as a white solid. LCMS (ESI, m / z): 508, 510 [M+H]+. Step 5: 1-(4-{6-bromo-1-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-1,2,3-benzotriazol-4- yl}piperazin-1-yl)-2-methylpropan-1-one. To a stirred solution of ethyl 5-{6-bromo-4-[4-(2-methylpropanoyl)piperazin-1-yl]- 1,2,3-benzotriazol-1-yl}-1,3,4-thiadiazole-2-carboxylate (500 mg, 0.983 mmol, 1 equiv) in DCM (10 mL) was added DIBAl-H (1 M in DCM, 1.97 mL, 1.966 mmol, 2 equiv) at -78 °C under nitrogen atmosphere. The resulting mixture was stirred for 4 h at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. The reaction was quenched by the addition of potassium sodium tartrate (aq., 50 mL) at 0 °C. The resulting mixture was extracted with DCM (3 x 80 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-(4-{6-bromo-1-[5-(hydroxymethyl)- 1,3,4-thiadiazol-2-yl]-1,2,3-benzotriazol-4-yl}piperazin-1-yl)-2-methylpropan-1-one (200 mg, 39.25%) as a light yellow oil. LCMS (ESI, m / z): 466, 468[M+H]+. Step 6: 1-{4-[6-bromo-1-(5-{[(tert-butyldimethylsilyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)- 1,2,3-benzotriazol-4-yl]piperazin-1-yl}-2-methylpropan-1-one. To a stirred mixture of 1-(4-{6-bromo-1-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]- 1,2,3-benzotriazol-4-yl}piperazin-1-yl)-2-methylpropan-1-one (200 mg, 0.429 mmol, 1 Attorney Docket No.: 53238-0005WO1 equiv) and imidazole (58.39 mg, 0.858 mmol, 2 equiv) in DCM (5 mL) was added TBSCl (96.96 mg, 0.643 mmol, 1.5 equiv) at 0 °C .The resulting mixture was stirred for 3 h at room temperature. The resulting mixture was diluted with DCM (30 mL). The resulting mixture was washed with water (3 x 20 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford 1-{4-[6-bromo-1-(5-{[(tert-butyldimethylsilyl)oxy]methyl}-1,3,4- thiadiazol-2-yl)-1,2,3-benzotriazol-4-yl]piperazin-1-yl}-2-methylpropan-1-one (200 mg, 72.29%) as a yellow solid. LCMS (ESI, m / z): 580, 582 [M+H]+. Step 7: 3-(5-{[(tert-butyldimethylsilyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-N-(3-methyloxetan- 3-yl)-7-[4-(2-methylpropanoyl) piperazin-1-yl]-1,2,3-benzotriazole-5-sulfonamide. A mixture of 1-{4-[6-bromo-1-(5-{[(tert-butyldimethylsilyl)oxy]methyl}-1,3,4- thiadiazol-2-yl)-1,2,3-benzotriazol-4-yl]piperazin-1-yl}-2-methylpropan-1-one (200 mg, 0.344 mmol, 1 equiv), TEAB (86.87 mg, 0.413 mmol, 1.2 equiv), HCOONa (70.28 mg, 1.032 mmol, 3 equiv), PPh3 (27.10 mg, 0.103 mmol, 0.3 equiv), 1,10-phenanthroline (18.62 mg, 0.103 mmol, 0.3 equiv), Pd(OAc)2 (7.73 mg, 0.034 mmol, 0.1 equiv) and K2S2O5 (168.48 mg, 0.757 mmol, 2.2 equiv) in DMSO (5 mL) was stirred for 4 h at 70 °C under nitrogen atmosphere. To the above mixture was added 3-methyloxetan-3-amine (45.01 mg, 0.516 mmol, 1.5 equiv) and NBS (153.27 mg, 0.860 mmol, 2.5 equiv) in THF (2 mL) dropwise at 0 °C under nitrogen atmosphere. The final reaction mixture was stirred for 1 h at room temperature under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was diluted with water (30 mL). The mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC, eluted with PE / EA (1:3) to afford 3-(5- {[(tert-butyldimethylsilyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-N-(3-methyloxetan-3-yl)-7-[4- (2-methylpropanoyl) piperazin-1-yl]-1,2,3-benzotriazole-5-sulfonamide (50 mg, 20.07%) as a yellow solid. LCMS (ESI, m / z): 651[M+H]+. Step 8: 3-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-N-(3-methyloxetan-3-yl)-7-(4- propanoylpiperazin-1-yl)-1,2,3-benzotriazole-5-sulfonamide. A solution of 3-(5-{[(tert-butyldimethylsilyl)oxy]methyl}-1,3,4-thiadiazol-2-yl)-N-(3- methyloxetan-3-yl)-7-[4-(2-methylpropanoyl)piperazin-1-yl]-1,2,3-benzotriazole-5- sulfonamide (40 mg, 0.061 mmol, 1 equiv) in THF (5 mL) was added HF-pyridine (1 Attorney Docket No.: 53238-0005WO1 mL) dropwise. The mixture was stirred for 3 h at room temperature. The reaction was monitored by LCMS. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions (Column: XBridge Shield RP 18 OBD Column, 30*150 mm, 5μm; Mobile Phase A: Water (10mmol / L NH4HCO3 + 0.1% NH3-H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min mL / min; Gradient: 23% B to 53% B in7min; Wave Length: 254nm nm; RT1(min): 6.33) to afford 3- [5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-N-(3-methyloxetan-3-yl)-7-(4-propanoylpiperazin- 1-yl)-1,2,3-benzotriazole-5-sulfonamide (2.6 mg, 8.08%) as a light-green solid. LCMS (ESI, m / z): 537.20 [M+H]+.1H NMR (300 MHz, Chloroform-d) δ=8.41 (s, 1H), 7.16 (s, 1H), 5.68 (s, 1H), 5.17 (s, 2H), 4.77 (d, J = 6.6 Hz, 2H), 4.35 (d, J = 6.6 Hz, 2H), 4.04-3.98 (m, 2H), 3.95-3.79 (m, 6H), 3.03-2.97 (m, 1H), 2.95-2.80 (m, 1H), 1.66 (s, 3H), 1.19 (d, J = 6.6 Hz, 6H). Example 3: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3- benzodiazole-5-sulfonyl chloride Step 1: N-ethyl-5-fluoro-2-nitroaniline. To a stirred mixture of 2,4-difluoro-1-nitro-benzene (3. g, 18.86 mmol, 1 equiv) and ethylamine (0.85 g, 18.86 mmol, 1 equiv) in 1,4-dioxane (50 mL) was added K2CO3(5.21 g, 37.71 mmol, 2 equiv) dropwise at room temperature. The reaction wording according to LCMS. The mixture was filtered. The filtrate was added with H2O (100 mL) and extracted by EtOAc (100 mL x 3). The organic layer was combined, washed by brine (200 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford N-ethyl-5-fluoro-2- nitroaniline (1.5 g) as an off-white solid. LCMS (ESI, m / z): 185.10 [M+H]+. Step 2: N1-ethyl-5-fluorobenzene-1,2-diamine. Attorney Docket No.: 53238-0005WO1 A mixture of N-ethyl-5-fluoro-2-nitroaniline (660 mg, 3.58 mmol, 1 equiv), Pd / C (381.37 mg, 0.36 mmol, 0.1 equiv, 10%) and H2(excess) in MeOH (10 mL) was stirred for 16h at room temperature. The resulting mixture was filtered, the filter cake was washed with MeOH (3 x 5 mL). To afford N1-ethyl-5-fluorobenzene-1,2-diamine) as an off- white solid. LCMS (ESI, m / z): 185.10 [M+H]+Step 3: 1-ethyl-6-fluoro-1,3-dihydro-2H-benzo[d]imidazol-2-one. A mixture of N1-ethyl-5-fluorobenzene-1,2-diamine (1.04 g, 6.754 mmol, 1 equiv) and CDI (1.10 g, 6.754 mmol, 1 equiv) in THF (30 mL) was stirred for 16 h at 60oC. Water was added and the resulting mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with water (3 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. LCMS (ESI, m / z): 181.05 [M+H]+. Step 4: 1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-5-fluoro-1,3-dihydro-2H- benzo[d]imidazol-2-one. A mixture of 1-ethyl-6-fluoro-3H-1,3-benzodiazol-2-one (500 mg, 2.775 mmol, 1 equiv) ,CuI (158.55 mg, 0.832 mmol, 0.3 equiv) ,K2CO3 (1150.55 mg, 8.325 mmol, 3 equiv) ,(1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (197.36 mg, 1.387 mmol, 0.5 equiv) and 2-bromo-5-(difluoromethyl)-1,3,4-thiadiazole (596.67 mg, 2.775 mmol, 1 equiv) in 1,4-dioxane (10 mL) was stirred for 4h at 80 °C. Add water, the resulting mixture was extracted with EtOAc (3 x10 mL). The combined organic layers were washed with water (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. LCMS (ESI, m / z): 315.05 [M+H]+. Step 5: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-benzodiazole- 5-sulfonyl chloride. The mixture of 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-5-fluoro-1,3- benzodiazol-2-one (30 mg, 0.095 mmol, 1 equiv) in HSO3Cl (0.5 mL, 7.595 mmol, 79.57 equiv) was stirred at 0 °C for 1 h under N2 atmosphere. The desired product wasdetected by LCMS. The mixture was diluted by DCM (3 mL) and concentrated under reduced pressure. The procedure was repeated three times. The residue was diluted with EtOAc (5 mL) and quenched by ice. The organic was washed by brine, dried over Na2SO4, filtered and concentrated to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo- Attorney Docket No.: 53238-0005WO1 1,3-benzodiazole-5-sulfonyl chloride (30 mg, 76.14%) as yellow oil. LCMS (ESI, m / z): 412.95 [M+H]+Step 6: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-N-(3-methyloxetan-3- yl)-2-oxo-1,3-benzodiazole-5-sulfonamide. To the mixture of 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo- 1,3-benzodiazole-5-sulfonyl chloride (25 mg, 0.061 mmol, 1 equiv) in DMF (1 mL, 12.922 mmol, 213.36 equiv) was added 3-methyloxetan-3-amine (7.91 mg, 0.091 mmol, 1.5 equiv) and TEA (12.26 mg, 0.122 mmol, 2 equiv). The mixture was stirred at room temperature for 16 h under nitrogen atmosphere. The desired product was detected by LCMS. The mixture was purified by Prep-HPLC with the following conditions (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol / L NH4HCO3+ 0.1% NH3-H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 30% B to 60% B in 7 min, 60% B; Wave Length: 254 nm; RT1(min): 6; to afford 3-[5-(difluoromethyl)-1,3,4- thiadiazol-2-yl]-1-ethyl-6-fluoro-N-(3-methyloxetan-3-yl)-2-oxo-1,3-benzodiazole-5- sulfonamide (3.7 mg, 13.18%) as a white solid. LCMS (ESI, m / z): 464.05 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ=879-8.64 (m, 2H), 7.50-7.88 (m, 2H), 4.64 (d, J=6.0 Hz, 2H), 4.17 (d, J = 6.4 Hz, 2H), 4.04-4.10 (m, 2H), 1.46 (s, 3H), 1.31 (d, J = 7.2 Hz, 3H). Example 4: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-(3-methyloxetan-3- yl)-2-oxo-1-(prop-2-yn-1-yl)-1,3-benzodiazole-5-sulfonamide Step 1: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-(3-methyloxetan-3-yl)-2-oxo- 1H-1,3-benzodiazole-5-sulfonamide. To a stirred solution of 3-methyloxetan-3-amine (90.58 mg, 1.040 mmol, 2 equiv) in DMF (1.5 mL) and TEA (0.5 mL, 3.597 mmol, 6.92 equiv) was added 3-[5- (difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1H-1,3-benzodiazole-5-sulfonyl Attorney Docket No.: 53238-0005WO1 chloride (200 mg, 0.520 mmol, 1 equiv) in DMF (1 mL) dropwise at 0 °C. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored by LCMS. Then water (30 mL) was added. The mixture was extracted with EA (3×20 mL), the combined organic layers were washed with brine (2 × 30 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (eluting with 1:1 EA / PE) to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N- (3-methyloxetan-3-yl)-2-oxo-1H-1,3-benzodiazole-5-sulfonamide (170 mg, 67.60%) as a yellow solid. LCMS (ESI, m / z): 436 [M+H]+. Step 2: N-{1-acetyl-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1,3- benzodiazol-5-ylsulfonyl}-N-(3-methyloxetan-3-yl)acetamide. A mixture of 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-(3- methyloxetan-3-yl)-2-oxo-1H-1,3-benzodiazole-5-sulfonamide (170 mg, 0.390 mmol, 1 equiv) and acetic anhydride (398.60 mg, 3.900 mmol, 10 equiv) in pyridine (3 mL) was stirred for 16 h at room temperature. The reaction was monitored by LCMS. Then water (30 mL) was added. The mixture was extracted with DCM (3 × 20 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4 and concentrated to afford N-{1-acetyl-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1,3- benzodiazol-5-ylsulfonyl}-N-(3-methyloxetan-3-yl)acetamide (150 mg, crude) as a yellow solid. LCMS (ESI, m / z): 520 [M+H]+. Step 3: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-(3-methyloxetan-3-yl)-2-oxo- 1-(prop-2-yn-1-yl)-1,3-benzodiazole-5-sulfonamide. A mixture of N-{1-acetyl-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2- oxo-1,3-benzodiazol-5-ylsulfonyl}-N-(3-methyloxetan-3-yl)acetamide (50 mg, 0.096 mmol, 1 equiv), K2CO3 (39.91 mg, 0.288 mmol, 3 equiv) and 3-bromoprop-1-yne (22.90 mg, 0.192 mmol, 2 equiv) in DMF (2 mL) was stirred for 16 h at 50 °C under N2atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. Then NH3-H2O (2 mL) was added and stirred for 12 h. The reaction was monitored by LCMS. The mixture was added water (30 mL) and extracted with DCM (3 × 20 mL), the combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC with the following conditions: (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH3-H2O), Mobile Phase B: ACN; Flow rate: 60 Attorney Docket No.: 53238-0005WO1 mL / min; Gradient: 30% B to 60% B in 7 min; WaveLength: 254 nm; RT1(min): 5.87) to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-(3-methyloxetan-3-yl)-2-oxo- 1-(prop-2-yn-1-yl)-1,3-benzodiazole-5-sulfonamide (9.3 mg, 19.87%) as a yellow solid. LCMS (ESI, m / z): 474.05 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ=8.76-8.69 (m, 2H), 7.80-7.72 (m, 1H), 7.66-7.49 (m, 1H), 4.92 (s, 2H), 4.64 (d, J = 6.0 Hz, 2H), 4.18 (d, J = 6.4 Hz, 2H), 3.52 (s, 1H), 1.45 (s, 3H). Example 5: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-N-[3- (fluoromethyl)oxetan-3-yl]-2-oxo-1,3-benzodiazole-5-sulfonamide To the mixture of 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo- 1,3-benzodiazole-5-sulfonyl chloride (30 mg, 0.073 mmol, 1 equiv) in DMF (1 mL) was added 3-(fluoromethyl)oxetan-3-amine hydrochloride (15.43 mg, 0.109 mmol, 1.5 equiv) and TEA (14.71 mg, 0.146 mmol, 2 equiv). The mixture was stirred at room temperature for 2 h. Desired product could be detected by LCMS. The mixture was purified by Prep-HPLC with the following conditions (Column: XBridge Prep Phenyl OBD Column, 19*250 mm, 5μm; Mobile Phase A: Water(10 mmol / L NH4HCO3+ 0.1% NH3-H2O), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient: 35% B to 60% B in 10 min, 60% B; Wave Length: 254 nm; RT1(min): 8; to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl- 6-fluoro-N-[3-(fluoromethyl)oxetan-3-yl]-2-oxo-1,3-benzodiazole-5-sulfonamide (3.2 mg, 9.08%) as a white solid. LCMS (ESI, m / z): 482.05 [M+H]+.1H NMR (300 MHz, DMSO-d6) δ=8.96 (s, 1H), 8.73 (d, J=6.6 Hz, 1H), 7.89-7.42 (m, 2H), 4.69-4.60 (m, 3H), 4.58-4.53 (m, 1H), 4.38 (d, J=6.9 Hz, 2H), 4.05-3.98 (m, 2H), 1.31 (d, J=7.2 Hz, 3H). Example 6: N-(3-cyanooxetan-3-yl)-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl- 6-fluoro-2-oxo-1,3-benzodiazole-5-sulfonamide Attorney Docket No.: 53238-0005WO1 To the mixture of 3-[5- - thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo- 1,3-benzodiazole-5-sulfonyl chloride (30 mg, 0.073 mmol, 1 equiv) in pyridine (2 mL) was added 3-aminooxetane-3-carbonitrile hydrochloride (14.67 mg, 0.109 mmol, 1.5 equiv). The mixture was stirred at room temperature for 2 h. Desired product could be detected by LCMS. The mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: (Column: XBridge Prep OBD C18 Column, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol / L NH4HCO3+ 0.1% NH3- H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 17% B to 47% B in 7 min, 47% B; Wave Length: 254 nm; RT1(min): 5.02; to afford N-(3-cyanooxetan-3-yl)-3-[5- (difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-benzodiazole-5- sulfonamide (9.8 mg, 27.67%) as an off-white semi-solid. LCMS (ESI, m / z): 475.05 [M+H]+.1H NMR (300 MHz, DMSO-d6) δ=9.64 (s, 1H), 8.73 (d, J=6.6 Hz, 1H), 7.92-7.45 (m, 2H), 4.84 (d, J=7.2 Hz, 2H), 4.76 (d, J=7.2 Hz, 2H), 3.95-4.10 (m, 2H), 1.31 (t, J=7.2 Hz, 3H). Example 7: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-[3- (fluoromethyl)oxetan-3-yl]-2-oxo-1-(prop-2-yn-1-yl)-1,3-benzodiazole-5-sulfonamide Step 1: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1H-1,3-benzodiazole-5- sulfonyl chloride. A mixture of 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-5-fluoro-3H-1,3- benzodiazol-2-one (200 mg, 0.699 mmol, 1 equiv) in ClSO3H (1 mL) was stirred for 2 h at Attorney Docket No.: 53238-0005WO1 60 °C. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The resulting mixture was diluted with EA (4 mL). The reaction was quenched by the addition of water (30 mL) at 0 °C. The mixture was extracted with EA (3 × 25 mL), the combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4 and concentrated to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2- oxo-1H-1,3-benzodiazole-5-sulfonyl chloride (200 mg, 74.40%) as a yellow solid. LCMS (ESI, m / z): 385 [M+H]+. Step 2: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-[3-(fluoromethyl)oxetan-3- yl]-2-oxo-1H-1,3-benzodiazole-5-sulfonamide. To a stirred solution of 3-(fluoromethyl)oxetan-3-amine hydrochloride (147.68 mg, 1.040 mmol, 2 equiv) in DMF (1.5 mL) and DIEA (0.5 mL) was added 3-[5- (difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1H-1,3-benzodiazole-5-sulfonyl chloride (200 mg, 0.520 mmol, 1 equiv) in DMF (1 mL) dropwise at 0 °C. The resulting mixture was stirred for 2h at room temperature. The reaction was monitored by LCMS. Then water (30 mL) was added. The mixture was extracted with EA (3×20 mL), the combined organic layers were washed with brine (2×30 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (eluting with 1:1 EA / PE) to afford 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N- [3-(fluoromethyl)oxetan-3-yl]-2-oxo-1H-1,3-benzodiazole-5-sulfonamide (20 mg, 6.79%) as a yellow solid. LCMS (ESI, m / z): 454 [M+H]+. Step 3: 1-acetyl-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-[3- (fluoromethyl)oxetan-3-yl]-2-oxo-1,3-benzodiazole-5-sulfonamide. A mixture of 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-[3- (fluoromethyl)oxetan-3-yl]-2-oxo-1H-1,3-benzodiazole-5-sulfonamide (100 mg, 0.221 mmol, 1 equiv) and acetic anhydride (225.17 mg, 2.210 mmol, 10 equiv) in pyridine (3 mL) was stirred for 16 h at room temperature. The reaction was monitored by LCMS. Then water (20 mL) was added. The mixture was extracted with DCM (3 × 20 mL), the combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4 and concentrated to afford 1-acetyl-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-[3- (fluoromethyl)oxetan-3-yl]-2-oxo-1,3-benzodiazole-5-sulfonamide (60 mg, 54.91%) as a yellow solid. LCMS (ESI, m / z): 538 [M+H]+. Attorney Docket No.: 53238-0005WO1 Step 4: 3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-[3-(fluoromethyl)oxetan-3- yl]-2-oxo-1-(prop-2-yn-1-yl)-1,3-benzodiazole-5-sulfonamide. A mixture of 1-acetyl-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N-[3- (fluoromethyl) oxetan-3-yl]-2-oxo-1,3-benzodiazole-5-sulfonamide (60 mg, 0.121 mmol, 1 equiv), K2CO3 (50.21 mg, 0.363 mmol, 3 equiv) and 3-bromoprop-1-yne (28.81 mg, 0.242 mmol, 2 equiv) in DMF (1 mL) was stirred for 16 h at 50 °C under N2atmosphere. The reaction was monitored by LCMS. The mixture was allowed to cool down to room temperature. The reaction mixture was purified by prep-HPLC with the following conditio...

Claims

Attorney Docket No.: 53238-0005WO1 What is claimed is:

1. A compound of Formula I: or a pharmaceutically acceptable saltQ is NH or CH2; A is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Cy, or Cy-C1-4alkyl-, wherein said C1-6alkyl, C2-6 alkenyl, and C2-6 alkynyl of A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, (f),formula (g), formula (h), formula (i), formula (j), or formula (k):Attorney Docket No.: 53238-0005WO1or X2is N or CR2; X3is N or CR3; X4is N or CR4; X5is N or CR5; X6is N or CR6; X7is N or CR7; X8is N or CR8; X9is N or CR9; X10is N or CR10; X11is N or CR11; X12is N or CR12; X13is N or CR13; X14is N or CR14; X15is N or CR15; X16is N or CR16; X17is N or CR17; X18is N or CR18;Attorney Docket No.: 53238-0005WO1 X19is N or CR19; X20is N or CR20; X21is N or CR21; X22is N or CR22; X23is N or CR23; X24is N or CR24; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X1, X2, and X3are simultaneously N; wherein no more than two of X4, X5, and X6are simultaneously N; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X10, X11, and X12are simultaneously N; wherein no more than two of X13, X14, and X15are simultaneously N; wherein no more than two of X16, X17, and X18are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X22, X23, and X24are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1,Attorney Docket No.: 53238-0005WO1 NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; R1, R2, R4, R5, R7, R8, R10, R11, R13, R14, R16, R17, R19, R20, R22, R23, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4alkyl; R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)qORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RX1, RX3, RX4, RX5, RX6, RX7, RY1, RY2, RY4, RY5, RY6, RY8, RZ1, RZ2, RZ3, RZ5, RZ7, and RZ8are each independently selected from H, halo, C1-6alkyl, C2-6alkenyl, and 5- membered heteroaryl, wherein said C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl of RX1, RX3, RX4, RX5, RX6, RX7, RY1, RY2, RY4, RY5, RY6, RY8, RZ1, RZ2, RZ3, RZ5, RZ7, and RZ8are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;Attorney Docket No.: 53238-0005WO1 RW1, RW2, RW3, and RW4are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl, wherein the C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, aryl, C3-7 10 4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; each Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4,Attorney Docket No.: 53238-0005WO1 C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc3and Rd3, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4,membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl areAttorney Docket No.: 53238-0005WO1 each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, NHC1-4alkyl, N(C1-4alkyl)2, halo, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, and C1-6haloalkoxy; each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k), then A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl.

2. A compound of Formula I: or a pharmaceutically acceptable saltQ is NH or CH2; A is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, or Cy-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6alkenyl, and C2-6alkynyl of A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd, B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), formula (h), formula (i), formula (j), or formula (k):Attorney Docket No.: 53238-0005WO1X1is N or CR1; X2is N or CR2; X3is N or CR3; X4is N or CR4; X5is N or CR5; X6is N or CR6; X7is N or CR7; X8is N or CR8; X9is N or CR9; X10is N or CR10; X11is N or CR11;Attorney Docket No.: 53238-0005WO1 X12is N or CR12; X13is N or CR13; X14is N or CR14; X15is N or CR15; X16is N or CR16; X17is N or CR17; X18is N or CR18; X19is N or CR19; X20is N or CR20; X21is N or CR21; X22is N or CR22; X23is N or CR23; X24is N or CR24; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X1, X2, and X3are simultaneously N; wherein no more than two of X4, X5, and X6are simultaneously N; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X10, X11, and X12are simultaneously N; wherein no more than two of X13, X14, and X15are simultaneously N; wherein no more than two of X16, X17, and X18are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X22, X23, and X24are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N;Attorney Docket No.: 53238-0005WO1 each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C NRc1C NRc1C NRc1C C3-74 4 heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1,R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)qORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2,membered heteroaryl, wherein said C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl of RX1, RX3, RX4, RX5, RX6, RX7, RY1, RY2, RY4, RY5, RY6, RY8, RZ1, RZ2, RZ3, RZ5, RZ7, and RZ8are each optionally substituted with 1, 2, 3, or 4 substituents independently selected fromAttorney Docket No.: 53238-0005WO1 halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl- C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C NRc2Rd2, NRc2C NRc2Rd2, NRc2Rd2, NRc2C Rb2, NRc2C ORa2,7 cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3,10aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selectedAttorney Docket No.: 53238-0005WO1 from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc3and Rd3, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc4and Rd4, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;Attorney Docket No.: 53238-0005WO1 each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 haloalkoxy; each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k), then A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl.

3. A compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein: Q is NH or CH2; A is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, or Cy-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6alkenyl, and C2-6alkynyl of A are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd, B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), formula (h), formula (i), formula (j), or formula (k):Attorney Docket No.: 53238-0005WO1X1is N or CR1; X2is N or CR2; X3is N or CR3; X4is N or CR4;Attorney Docket No.: 53238-0005WO1 X5is N or CR5; X6is N or CR6; X7is N or CR7; X8is N or CR8; X9is N or CR9; X10is N or CR10; X11is N or CR11; X12is N or CR12; X13is N or CR13; X14is N or CR14; X15is N or CR15; X16is N or CR16; X17is N or CR17; X18is N or CR18; X19is N or CR19; X20is N or CR20; X21is N or CR21; X22is N or CR22; X23is N or CR23; X24is N or CR24; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X1, X2, and X3are simultaneously N; wherein no more than two of X4, X5, and X6are simultaneously N; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X10, X11, and X12are simultaneously N; wherein no more than two of X13, X14, and X15are simultaneously N;Attorney Docket No.: 53238-0005WO1 wherein no more than two of X16, X17, and X18are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X22, X23, and X24are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; R1, R2, R4, R5, R7, R8, R10, R11, R13, R14, R16, R17, R19, R20, R22, R23, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4 alkyl; R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2,Attorney Docket No.: 53238-0005WO1 NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;of RX1, RX3, RX4, RX5, RX6, RX7, RY1, RY2, RY4, RY5, RY6, RY8, RZ1, RZ2, RZ3, RZ5, RZ7, and RZ8are each substituted with or 4 substituents selected frommembered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl- C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW2, RW3, and RW4are each independently selected from C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3- 7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3,is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4Attorney Docket No.: 53238-0005WO1 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc3and Rd3, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;Attorney Docket No.: 53238-0005WO1 or Rc4and Rd4, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 haloalkoxy; and each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4 alkyl, and CN; wherein when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k), then A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein Q is NH.

5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein Q is CH2.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein A is Cy.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A is selected from C3-7cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.Attorney Docket No.: 53238-0005WO1 8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein A is C3-7cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein A is cyclopropyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.

10. The compound of any one of claims 7-9, or a pharmaceutically acceptable salt thereof, wherein at least one RCyis C1-6alkyl.

11. The compound of any one of claims 7-9, or a pharmaceutically acceptable salt thereof, wherein at least one RCyis methyl.

12. The compound of any one of claims 7-9, or a pharmaceutically acceptable salt thereof, wherein at least one RCyis CN.

13. The compound of any one of claims 7-9, or a pharmaceutically acceptable salt thereof, wherein the cyclopropyl is substituted with methyl and CN.

14. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.

15. The compound of any one of claims 1-6 and 14, or a pharmaceutically acceptable salt thereof, wherein A is oxetanyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.

16. The compound of claim 14 or 15, or a pharmaceutically acceptable salt thereof, wherein at least one RCyis C1-6 alkyl, C1-6 haloalkyl, or CN.

17. The compound of claim 14 or 15, or a pharmaceutically acceptable salt thereof, wherein at least one RCyis methyl, fluoromethyl, or CN.Attorney Docket No.: 53238-0005WO1 18. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A is selected , ONRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3.

19. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt ,C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; RCy”is selected from halo, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl- C1-4alkyl, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1,Attorney Docket No.: 53238-0005WO1 C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1,n an o is an integer selected from 0, 1, 2, and 3.

20. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A is selected ,OC(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; o is an integer selected from 0, 1, 2, and 3; and p is an integer selected from 0, 2, 3, 4, and 5.Attorney Docket No.: 53238-0005WO1 21. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A is selected m is an integer selected22. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A m is an 0, 1, 2, 3, 4, and 5.

23. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein m is an integer selected from 0, 2, 3, 4, and 5.

24. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein m is 2.

25. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A is selected ; and m is an integer selected4, and 5.

26. The compound of claim 25, or a pharmaceutically acceptable salt thereof, wherein m is 1.

27. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein A is selected ,.Attorney Docket No.: 53238-0005WO1 28. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt ,thereof, wherein A is selected .

30. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein each RCyis independently selected from halo, C2-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1.

31. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein each RCyis independently selected from halo, C2-6 alkenyl, C2-6 alkynyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C2-6Attorney Docket No.: 53238-0005WO1 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1.

32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), formula (i), or formula (k):Attorney Docket No.: 53238-0005WO1 33. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (h):

34. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (h):Attorney Docket No.: 53238-0005WO135. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (i), formula (j), or formula (k):

36. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (i) or formula (k):Attorney Docket No.: 53238-0005WO1 37. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (i):

38. The compound of any one or a acceptable salt thereof, wherein B is of formula (k):

39. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (c), formula (g), formula (i), formula (j), or formula (k):Attorney Docket No.: 53238-0005WO1 40.acceptable salt thereof, wherein B is of formula (c), formula (g), formula (i), or formula (k):

41. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (c):Attorney Docket No.: 53238-0005WO1 42. The compound of claim 41, or a pharmaceutically acceptable salt thereof, wherein X7is CR7, X8is CR8, and X9is CR9.

43. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein R7is H.

44. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein R8is selected from H, fluoro, and bromo.

45. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein R9is selected from H and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.

46. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein R9,Attorney Docket No.: 53238-0005WO1 47. The compound of any one of claims 41-46, or a pharmaceutically acceptable salt thereof, wherein RX3is selected from C1-6alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’.

48. The compound of any one of claims 41-46, or a pharmaceutically acceptable salt thereof, wherein RX3is C1-6alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN.

49. The compound of any one of claims 41-46, or a pharmaceutically acceptable salt thereof, wherein RX3is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6alkyl.

50. The compound of any one of claims 41-46, or a pharmaceutically acceptable salt thereof, wherein RX3is selected from.

51. The compound of any one of claims 41-46, or a pharmaceutically acceptable salt thereof, wherein RX3is selected .

52. The compound of any one of claims 41-46, or a pharmaceutically acceptable salt thereof, wherein RZ3is selected from H and halo.

53. The compound of any one of claims 41-46, or a pharmaceutically acceptable salt thereof, wherein RZ3is selected from H and chloro.Attorney Docket No.: 53238-0005WO1 54. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein B is of formula (i):

55. The compound of claimacceptable salt thereof, wherein X25is CR25, X26is CR26, and X27is CR27.

56. The compound of claim 55, or a pharmaceutically acceptable salt thereof, wherein R25is H.

57. The compound of claim 55, or a pharmaceutically acceptable salt thereof, wherein R26is selected from H, fluoro, and bromo.

58. The compound of claim 55, or a pharmaceutically acceptable salt thereof, wherein R27is selected from H and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.Attorney Docket No.: 53238-0005WO1 59. The compound of claim 55, or a pharmaceutically acceptable salt thereof, wherein R27,any one or a thereof, wherein RW1is selected from C1-6 alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’.

61. The compound of any one of claims 54-59, or a pharmaceutically acceptable salt thereof, wherein RW1is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN.

62. The compound of any one of claims 54-59, or a pharmaceutically acceptable salt thereof, wherein RW1is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6 alkyl.

63. The compound of any one of claims 54-59, or a pharmaceutically acceptable salt thereof, wherein RW1is selected fromAttorney Docket No.: 53238-0005WO1 64. The compound of any one of claims 54-59, or a pharmaceutically acceptable salt thereof, wherein RW1is selected .

65. The compound of any one ofor a acceptable salt thereof, wherein B is a group of formula (k):

66. The compound of claim 65, or a pharmaceutically acceptable salt thereof, wherein X31is CR31, X32is CR32, and X33is CR33.

67. The compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein R31is H.

68. The compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein R32is selected from H, fluoro, and bromo.

69. The compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein R33is selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5- 10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R3, R6, R9, R12, R15, R18, R21, R24, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)mORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2,Attorney Docket No.: 53238-0005WO1 NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.

70. The compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein R33is selected from H and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2.

71. The compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein R33, ,Attorney Docket No.: 53238-0005WO1 ,or a wherein R33,73. The compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein R33,Attorney Docket No.: 53238-0005WO1 , ,Attorney Docket No.: 53238-0005WO1 ,or a R33,75. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3and RW4are selected from H, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl,Attorney Docket No.: 53238-0005WO1 and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5- membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’.

76. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3and RW4are selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’.

77. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3and RW4are selected from C1-6alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’.

78. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3and RW4are C1-6alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN.

79. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3and RW4are 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6alkyl.

80. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, at least one of RW3and RW4is 1,3,4-thiadiazolyl optionally substituted with 1 R’.

81. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, at least one of RW3and RW4is 1,3,4-thiadiazolyl optionally substituted with difluoromethyl, trifluoromethyl, or methanol.Attorney Docket No.: 53238-0005WO1 82. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3and RW4are selected from H, methyl, ,.any one or a acceptable salt thereof, wherein RW3and RW4are selected from ,.

84. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3and RW4are selected from .

85. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein: RW3is selected from H, C1-6alkyl, and C3-7cycloalkyl, wherein the C1-6alkyl and C3-7cycloalkyl are optionally substituted with 1, 2, 3, or 4 R’; and RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 R’.

86. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3is C1-6 alkyl and RW4is 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’.Attorney Docket No.: 53238-0005WO1 87. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, NRc3Rd3, and CN.

88. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW3is C1-6 alkyl optionally substituted with 1, 2, 3, or 4 R’, selected from halo, ORa3, and CN.

89. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein RW4is 5-membered heteroaryl optionally substituted with 1, 2, 3, or 4 C1-6 alkyl.

90. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein: ;91. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein: .Attorney Docket No.: 53238-0005WO1 92. The compound of any one of claims 65-73, or a pharmaceutically acceptable salt thereof, wherein:

93. any one or a acceptable salt thereof, wherein B is of formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), formula (i), or formula (k):Attorney Docket No.: 53238-0005WO1 (i) (k); ;o is an integer selected from 0, 1, 2, and 3.

94. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (h):Attorney Docket No.: 53238-0005WO1 ;C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3.

95. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein B is of formula (a), formula (b), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (h):Attorney Docket No.: 53238-0005WO1 ;each is selected from from halo, CN, NO2, C(O) C(O) C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3.

96. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein B is of formula (i), formula (j), or formula (k):Attorney Docket No.: 53238-0005WO1 O ;C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3.

97. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein B is of formula (i) or formula (k): ;each RCy’is selected from from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1;Attorney Docket No.: 53238-0005WO1 m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3.

98. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein B is of formula (c), formula (g), formula (i), formula (j), or formula (k): ;each RCy’is selected from from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; and o is an integer selected from 0, 1, 2, and 3.Attorney Docket No.: 53238-0005WO1 99. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein B is of formula (c), formula (g), formula (i), formula (j), or formula (k): ;each RCy’is selected from from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; m is an integer selected from 0, 1, 2, 3, 4, and 5; o is an integer selected from 0, 1, 2, and 3; and p is an integer selected from 0, 2, 3, 4, and 5.

100. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein B is of formula (c), formula (g), formula (i), or formula (k):Attorney Docket No.: 53238-0005WO1 ;each RCy’is selected from from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1,o is an integer selected from 0, 1, 2, and 3.

101. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula II-A or II-B:Attorney Docket No.: 53238-0005WO1any one or a thereof, wherein the compound is of Formula II-1: wherein n is an103. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula III-A:

104. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula III-1:Attorney Docket No.: 53238-0005WO1 wherein n is an105. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IV-A or IV-B: R' N106. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IV-1: wherein n is anAttorney Docket No.: 53238-0005WO1 107. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula V-A or V-B:

108. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula V-1:wherein n is an integer selected from 0, 1, 2, 3, and 4.

109. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula VI-A or VI-B:Attorney Docket No.: 53238-0005WO1 110. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula II-1:wherein n is an 111. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula VII-A or VII-B:

112. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula VII-1:Attorney Docket No.: 53238-0005WO1 wherein n is an integer selected from 0, 1, 2, 3, and 4.

113. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula VIII-A or VIII-B: R' N114. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula VIII-1:wherein n is an integer selected from 0, 1, 2, 3, and 4.

115. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IX-A or IX-B:Attorney Docket No.: 53238-0005WO1 IX-A.

116. The compound of any one of or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IX-1: wherein n is an117. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula X-A or X-B:

118. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula X-1, X-2, or X-3:Attorney Docket No.: 53238-0005WO1wherein n is an integer selected from 0, 1, 2, 3, and 4.

119. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula XI-A or XI-B:

120. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula XI-1:Attorney Docket No.: 53238-0005WO1 wherein n is an121. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula XII-A or XII-B:

122. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula XII-1, XII-2, or XII-3:Attorney Docket No.: 53238-0005WO1 R N Nn an 123. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Q is NH or CH2; A is Cy or Cy-C1-4alkyl-; B is of formula (c), formula (g), formula (i), formula (j), or formula (k):Attorney Docket No.: 53238-0005WO1 X21is N or CR21; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents selected from C C CH, halo, and C1-4alkyl;Attorney Docket No.: 53238-0005WO1 R9, R21, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4- 10 membered heterocycloalkyl of R9, R21, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, (CH2)qORa2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RX3, RX7, RZ3, and RZ7are each independently selected from H, halo, C1-6alkyl, C2-6alkenyl, and 5-membered heteroaryl, wherein said C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl of RX3, RX7, RZ3, and RZ7are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2,6alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl- C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-Attorney Docket No.: 53238-0005WO1 7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; each Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl, wherein said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of Ra, Rb, Rc, Rd, Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rcand Rd, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc1and Rd1, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc2and Rd2, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituentsAttorney Docket No.: 53238-0005WO1 independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc3and Rd3, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; or Rc4and Rd4, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10aryl-C1-4alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, NHC1-4alkyl, N(C1-4alkyl)2, halo, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, and C1-6haloalkoxy; each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c), formula (g), or formula (k), then A is not 1- methylcyclopropyl, 1-cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

124. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Q is NH or CH2;Attorney Docket No.: 53238-0005WO1 A is Cy or Cy-C1-4 alkyl-; B is of formula (c), formula (i), or formula (k):or X25is N or CR25; X26is N or CR26; X27is N or CR27; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C3-7cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1- 6 haloalkyl, CN, NO2, ORa1, and NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, and NRc1Rd1; R7, R8, R25, R26, R31, and R32are each independently selected from H, halo, and C1-4 alkyl; R9, R27, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4Attorney Docket No.: 53238-0005WO1 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, (CH2)qORa2, ORa2, C(O)Rb2, C(O)NRc2Rd2, and C(O)ORa2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C OC OC C NRc2C6 7 6 C2-6 alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa3, and NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1- 6 haloalkyl, and C6-10 aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, and NRc3Rd3; each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, and 4-10 membered heterocycloalkyl,, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, and 4-10 membered heterocycloalkyl of Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4alkyl, C1-6haloalkyl, CN, and ORa4; each Ra4is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, amino, NHC1-4 alkyl, and N(C1-4alkyl)2; q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

125. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy; B is of formula (c), formula (i), or formula (k):Attorney Docket No.: 53238-0005WO1X25is CR25; X26is CR26; X27is CR27; X31is CR31; X32is CR32; X33is CR33; each Cy is independently selected from C3-7 cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from C1-6alkyl, C1-6haloalkyl, and CN; R7, R8, R25, R26, R31, and R32are each independently selected from H and halo; R9, R27, and R33are each independently selected from H, halo, and 4-10 membered heterocycloalkyl, wherein 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6alkyl, (CH2)qORa2, C(O)Rb2, and C(O)NRc2Rd2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 haloalkyl; RW1, RW2, RW3, and RW4are each independently selected from H, C1-6 alkyl, C2-6 alkynyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkynyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkynyl, and C1-6 haloalkyl, wherein the C1-6alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from ORa3;Attorney Docket No.: 53238-0005WO1 each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C3-7cycloalkyl, and 4-10 membered heterocycloalkyl,, wherein said C1-6alkyl, C3-7 cycloalkyl, and 4-10 membered heterocycloalkyl of Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-6 haloalkyl and ORa4; each Ra4is independently selected from H, C1-6alkyl, and N(C1-4alkyl)2; q is 1; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

126. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4 alkyl-; B is of formula (c), formula (g), formula (i), formula (j), or formula (k):X7is N or CR7; X8is N or CR8; X9is N or CR9; X19is N or CR19; X20is N or CR20;Attorney Docket No.: 53238-0005WO1 X21is N or CR21; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, CN, NO2, ORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl-C1-4alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1; R7, R8, R19, R20, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4alkyl; R9, R21, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-Attorney Docket No.: 53238-0005WO1 10 membered heterocycloalkyl of R9, R21, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, CN, NO2, (CH2)mORa2, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, 5-membered optionallyC2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4alkyl, 4-10 membered heterocycloalkyl-C1-4alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW2, RW3, and RW4are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; each Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, , wherein said C1-6alkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4,Attorney Docket No.: 53238-0005WO1 C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4; each Ra4, Rb4, Rc4, and Rd4is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 haloalkoxy; and each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4alkyl, and CN; and q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c), formula (g), or formula (k), then A is not 1- methylcyclopropyl, 1-cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

127. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4 alkyl-; B is a group of formula (c), formula (i) or formula (k):X9is N or CR9; X25is N or CR25; X26is N or CR26; X27is N or CR27; X31is N or CR31; X32is N or CR32; X33is N or CR33;Attorney Docket No.: 53238-0005WO1 wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C3-7cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, CN, NO2, ORa1, and NRc1Rd1, wherein the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, and NRc1Rd1; R7, R8, R25, R26, R31, and R32are each independently selected from H, halo, and C1-4 alkyl; R9, R27, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, (CH2)mORa2, ORa2, C(O)Rb2, C(O)NRc2Rd2, and C(O)ORa2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2,C3-7cycloalkyl, and 5-membered heteroaryl, wherein the C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa3, and NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, and NRc3Rd3; each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl; andAttorney Docket No.: 53238-0005WO1 q is an integer selected from 1, 2, 3, 4, 5, and 6; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

128. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy; B is a group of formula (c), formula (i), or formula (k):X9is CR9; X25is CR25; X26is CR26; X27is CR27; X31is CR31; X32is CR32; X33is CR33; each Cy is independently selected from C3-7 cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from C1-6 alkyl, C1-6 haloalkyl, and CN; R7, R8, R25, R26, R31, and R32are each independently selected from H and halo; R9, R27, and R33are each independently selected from H, halo, and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C(O)NRc2Rd2, (CH2)mORa2, and C(O)Rb2;Attorney Docket No.: 53238-0005WO1 RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 haloalkyl; RW1, RW3, and RW4are each independently selected from H, C1-6alkyl, C3-7cycloalkyl, and 5-membered heteroaryl, wherein the C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, and 5-membered heteroaryl are optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkynyl, and C1-6 haloalkyl, wherein the C1-6alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from ORa3; each Rb2, Rc2, Rd2, and Ra3is independently selected from H and C1-6alkyl; and q is 1; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

129. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4 alkyl-; B is of formula (c), formula (g), formula (i), formula (j), or formula (k):Attorney Docket No.: 53238-0005WO1 X7is N or CR7; X8is N or CR8; X9is N or CR9; X19is N or CR19; X20is N or CR20; X21is N or CR21; X25is N or CR25; X26is N or CR26; X27is N or CR27; X28is N or CR28; X29is N or CR29; X30is N or CR30; X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X19, X20, and X21are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X28, X29, and X30are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, CN, NO2, ORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl-C1-4 alkyl, C3-7cycloalkyl-C1-4alkyl, 5-10 membered heteroaryl-C1-4alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1;Attorney Docket No.: 53238-0005WO1 R7, R8, R19, R20, R25, R26, R28, R29, R31, and R32are each independently selected from H, halo, and C1-4alkyl; R9, R21, R27, R30, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10aryl, C3-7cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4- 10 membered heterocycloalkyl of R9, R21, R27, R30, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, CN, NO2, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRcC(O)ORa2, NRcC(O)NRc2Rd2, NRcS(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RX3, RX7, RZ3, and RZ7are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3, RX7, RZ3, and RZ7are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW2, RW3, and RW4are each independently selected from C1-6 alkyl, C2-6 alkenyl, and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3;Attorney Docket No.: 53238-0005WO1 each Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, , wherein said C1-6alkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra1, Rb1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rb3, Rc3, and Rd3is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C NRc4C C NRc4C S66 6 6 6C2-6alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, and C1-6haloalkoxy; and each Re, Re1, Re2, Re3, and Re4is independently selected from H, C1-4 alkyl, and CN; wherein when B is formula (c), formula (g), or formula (k), then A is not 1- methylcyclopropyl, 1-cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

130. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy or Cy-C1-4 alkyl-; B is a group of formula (c), formula (i) or formula (k):Attorney Docket No.: 53238-0005WO1 X31is N or CR31; X32is N or CR32; X33is N or CR33; wherein no more than two of X7, X8, and X9are simultaneously N; wherein no more than two of X25, X26, and X27are simultaneously N; wherein no more than two of X31, X32, and X33are simultaneously N; each Cy is independently selected from C3-7 cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6 haloalkyl, CN, NO2, ORa1, and NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of RCyis optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, and NRc1Rd1; R7, R8, R25, R26, R31, and R32are each independently selected from H, halo, and C1-4alkyl; R9, R27, and R33are each independently selected from H, halo, ORa2, NRc2Rd2, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R9, R27, and R33are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa2, C(O)Rb2, C(O)NRc2Rd2, and C(O)ORa2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; RW1, RW3, and RW4are each independently selected from C1-6alkyl, C2-6alkenyl, and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, CN, NO2, ORa3, and NRc3Rd3, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6haloalkyl, and C6-10aryl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, ORa3, and NRc3Rd3;Attorney Docket No.: 53238-0005WO1 each Ra1, Rc1, Rd1, Ra2, Rb2, Rc2, Rd2, Ra3, Rc3, and Rd3is independently selected from H, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

131. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: Q is NH; A is Cy; B is a group of formula (c), formula (i), or formula (k):X9is CR9; X25is CR25; X26is CR26; X27is CR27; X31is CR31; X32is CR32; X33is CR33; each Cy is independently selected from C3-7 cycloalkyl and 4-10 membered heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy; each RCyis independently selected from C1-6 alkyl, C1-6 haloalkyl, and CN; R7, R8, R25, R26, R31, and R32are each independently selected from H and halo; R9, R27, and R33are each independently selected from H, halo, and 4-10 membered heterocycloalkyl, wherein said 4-10 membered heterocycloalkyl of R9, R27, and R33are eachAttorney Docket No.: 53238-0005WO1 optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C(O)NRc2Rd2, and C(O)Rb2; RX3and RZ3are each independently selected from H, halo, and 5-membered heteroaryl, wherein said 5-membered heteroaryl of RX3and RZ3are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 haloalkyl; RW1, RW3, and RW4are each independently selected from C1-6alkyl and 5-membered heteroaryl, each optionally substituted with 1, 2, 3, or 4 R’; each R’ is independently selected from halo, C1-6alkyl, C2-6alkynyl, and C1-6haloalkyl, wherein the C1-6 alkyl of R’ is optionally substituted with 1, 2, or 3 groups independently selected from ORa3; each Rb2, Rc2, Rd2, and Ra3is independently selected from H and C1-6 alkyl; wherein when B is formula (c) or formula (k), then A is not 1-methylcyclopropyl, 1- cyanocyclopropyl, or 1-(fluoromethyl)cyclopropyl.

132. The compound of any one of claims 123-131, or a pharmaceutically acceptable salt thereof, wherein B is a group of formula (i) or formula (k):

133. The compound of any one of claims 123-131, or a pharmaceutically acceptable salt thereof, wherein B is a group of formula (i):

134. The compound of any one of claims 123-131, or a pharmaceutically acceptable salt thereof, wherein B is a group of formula (k):Attorney Docket No.: 53238-0005WO1135. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k); A is Cy; and Cy is C3-7cycloalkyl, then Cy is substituted with 0, 2, 3, 4, or 5 substituents independently selected from RCy.

136. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: when B is formula (a), formula (c), formula (d), formula (e), formula (f), formula (g), or formula (k); and A is Cy; then Cy is C4-7cycloalkyl substituted with 1, 2, 3, 4, or 5 substituents independently selected from RCy.

137. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein A is not 1-methylcyclopropyl, 1-cyanocyclopropyl, or 1- (fluoromethyl)cyclopropyl.

138. The compound of claim 1, selected from: {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-(2-methoxyethyl)-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine;Attorney Docket No.: 53238-0005WO1 {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 3-{3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-6-fluoro-2-oxo-1,3-dihydro- 1,3-benzimidazol-5-ylsulfonylamino}-3-oxetanecarbonitrile; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-2-oxo-1-(2-propynyl)-1,3- dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {7-bromo-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3- benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-(4-isobutyryl-1-piperazinyl)-6- (3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(4-isobutyryl-1-piperazinyl)-1,3-dihydro-1,3-benzimidazol-2-one; 1-(4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 1-(4-{1-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1H-1,2,3-benzotriazol-4-yl}-1-piperazinyl)-2-methyl-1-propanone; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-ethyl-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2- one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-3-(2,2,2-trifluoroethyl)-1,3-dihydro-1,3- benzimidazol-2-one; and 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-8-((3S,5S)-3,5-dimethylpiperazin-1-yl)- N-(3-methyloxetan-3-yl)imidazo[1,5-a]pyridine-6-sulfonamide; or a pharmaceutically acceptable salt of any of the aforementioned.

139. The compound of claim 1, selected from:Attorney Docket No.: 53238-0005WO1 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; {7-[(R)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl- 2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-(2,5-diazabicyclo[4.1.0]hept-2-yl)-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1- ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-1-cyclopropyl-3-[5-(difluoromethyl)-1,3,4- thiadiazol-2-yl]-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; N-(1-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-(3-methyl-3- oxetanylaminosulfonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-3-azepanyl)2- methylpropionamide; {7-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]- 1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3-oxetanyl)amine; {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}-1- piperazinecarboxamide; {7-[1-(N,N-dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl- 3-oxetanyl)amine; N,N-dimethyl-4-{1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-(2-hydroxyethyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-4-yl}- 1,2,3,6-tetrahydro-1-pyridinecarboxamide;Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-3-methyl-1,3-dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-6-(3-methyl-3- oxetanylaminosulfonyl)-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-1,3-dihydro-1,3- benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-(2-oxa-7-aza-7- spiro[3.5]nonyl)-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3- oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-{4-[(1-methoxycyclopropyl)carbonyl]- 1-piperazinyl}-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3- benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3-azetidinyl)carbonyl]-1-piperazinyl}-3-methyl- 1,3-dihydro-1,3-benzimidazol-2-one; 4-{(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl}-1-[5- (difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-1,3-benzimidazol-2-one; 4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2- yl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-1,3-benzimidazol-2-one; {7-[(R)-4-(N,N-dimethylcarbamoyl)-3-methyl-1-piperazinyl]-3-[5-(difluoromethyl)- 1,3,4-thiadiazol-2-yl]-1-ethyl-2-oxo-1,3-dihydro-1,3-benzimidazol-5-ylsulfonyl}(3-methyl-3- oxetanyl)amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(R)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(S)-3-(methoxymethyl)-1- piperazinyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine;Attorney Docket No.: 53238-0005WO1 6-[3-(fluoromethyl)-3-oxetanylaminosulfonyl]-4-{4-[(3-methoxy-3- azetidinyl)carbonyl]-1-piperazinyl}-3-methyl-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- 1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-isobutyryl-3-methyl-1-piperazinyl]-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(S)-4-isobutyryl-3-methyl-1-piperazinyl]-1,3-dihydro-2H-1,3- benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-7-[(2S,6S)-2,6-dimethyl-1,2,3,6- tetrahydro-4-pyridyl]-1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-7-[2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-[(R)-4-[(1- methoxycyclopropyl)carbonyl]-3-methyl-1-piperazinyl]-6-(3-methyl-3- oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-[(S)-4-isobutyryl-3-methyl-1- piperazinyl]-3-methyl-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3- benzimidazol-2-one; 3-(2-aminoethyl)-1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-(4-isobutyryl-1- piperazinyl)-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N,N- dimethylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(1-methoxycyclopropyl)carbonyl]-3-methyl-1- piperazinyl]-3-methyl-1,3-dihydro-2H-1,3-benzimidazol-2-one;Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[(R)-4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-3-methyl-1- piperazinyl]-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{1-[(1-methoxycyclopropyl)carbonyl]-1,2,3,6-tetrahydro-4- pyridyl}-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-4-{4-[(1- methoxycyclopropyl)carbonyl]-1-piperazinyl}-6-(3-methyl-3-oxetanylaminosulfonyl)-1,3- dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclopropyl)carbonyl]-1-piperazinyl}-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-3-ethyl-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(3-methoxy-1-methyl-3-azetidinyl)carbonyl]-1-piperazinyl}- 1,3-dihydro-2H-1,3-benzimidazol-2-one; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-methyl-2-oxo-7-(1,2,3,6-tetrahydro-4- pyridyl)-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-6-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(R)-3-methyl-4-(N- methylcarbamoyl)-1-piperazinyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-5-ylsulfonyl}[3- (fluoromethyl)-3-oxetanyl]amine; {3-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-1-ethyl-7-[(S)-2-methyl-1-(N,N- dimethylcarbamoyl)-1,2,3,6-tetrahydro-4-pyridyl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazol- 5-ylsulfonyl}[3-(fluoromethyl)-3-oxetanyl]amine;Attorney Docket No.: 53238-0005WO1 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-(1-isobutyryl-1,2,3,6-tetrahydro-4-pyridyl)-3-methyl-1,3-dihydro- 2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-{4-[(1-methoxycyclobutyl)carbonyl]-1-piperazinyl}-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one; 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-3-methyl-4-(4-{[(R)-1-methyl-2-azetidinyl]carbonyl}-1- piperazinyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; and 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-[3-(fluoromethyl)-3- oxetanylaminosulfonyl]-4-[4-(2-methoxy-2-methylpropionyl)-1-piperazinyl]-3-methyl-1,3- dihydro-2H-1,3-benzimidazol-2-one; or a pharmaceutically acceptable salt of any of the aforementioned.

140. The compound of claim 1, selected from: 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(1-(1-(2-hydroxyethoxy)cyclopropane-1-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-oxo- 2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-(4-(1-ethoxycyclopropane-1- carbonyl)piperazin-1-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-4-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N- (3-(fluoromethyl)oxetan-3-yl)-1H-benzo[d][1,2,3]triazole-6-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((3R,5R)-3,5-dimethylpiperazin-1-yl)-N- (3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-7-(4-(1-(2-fluoroethyl)-3- methoxyazetidine-3-carbonyl)piperazin-1-yl)-N-(3-(fluoromethyl)oxetan-3-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((3S,5R)-3,5-dimethylpiperazin-1-yl)-N- (3-(fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide;Attorney Docket No.: 53238-0005WO1 (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(1-methoxycyclopropane-1-carbonyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-((2S,6S)-2,6-dimethylmorpholino)-N-(3- (fluoromethyl)oxetan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5- sulfonamide; (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(1-methoxycyclobutane-1-carbonyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(4-(3-methoxyoxetane-3-carbonyl)piperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; (S)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3- yl)-7-(4-(2-methoxy-2-methylpropanoyl)-3-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-7-(4-(1-(2- (dimethylamino)ethoxy)cyclopropane-1-carbonyl)piperazin-1-yl)-1-methyl-N-(3- methyloxetan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide; 3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-N-(3-(fluoromethyl)oxetan-3-yl)- 7-(4-(1-(methoxy-d3)cyclopropane-1-carbonyl)piperazin-1-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-sulfonamide; 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N-dimethyl-3,6- dihydropyridine-1(2H)-carboxamide; 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N,2-trimethyl-3,6- dihydropyridine-1(2H)-carboxamide; and 4-(1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-3-ethyl-6-(N-(3-(fluoromethyl)oxetan- 3-yl)sulfamoyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N,N,6-trimethyl-3,6- dihydropyridine-1(2H)-carboxamide; or a pharmaceutically acceptable salt of any of the aforementioned.Attorney Docket No.: 53238-0005WO1 141. A pharmaceutical composition comprising a compound of any one of claims 1-140, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

142. A method of inhibiting the activity of PARG comprising contacting a compound of any one of claims 1-140, or a pharmaceutically acceptable salt thereof, with said PARG.

143. The method of claim 142, wherein the contacting is contacting in vitro.

144. A method of treating a disease or disorder in a patient in need of treatment comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1-140, or a pharmaceutically acceptable salt thereof, or a composition of claim 141.

145. The method of claim 144, wherein the disease or disorder is cancer.

146. The method of claim 145, wherein the cancer is a cellular stress-dependent cancer.

147. The method of claim 145, wherein said cancer is selected from lung cancer, colon cancer, breast cancer, ovarian cancer, gastric cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, skin cancer, bladder cancer, esophageal cancer, head and neck cancer, kidney cancer, rectal cancer, stomach cancer, thyroid cancer, uterine cancer, mantle cell lymphoma, and renal cell carcinoma.

Images